CN115636831A - Fused pyrimidinediones, their use and pharmaceutical compositions - Google Patents
Fused pyrimidinediones, their use and pharmaceutical compositions Download PDFInfo
- Publication number
- CN115636831A CN115636831A CN202211324140.5A CN202211324140A CN115636831A CN 115636831 A CN115636831 A CN 115636831A CN 202211324140 A CN202211324140 A CN 202211324140A CN 115636831 A CN115636831 A CN 115636831A
- Authority
- CN
- China
- Prior art keywords
- substituted
- int
- group
- unsubstituted
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 20
- 150000008512 pyrimidinediones Chemical class 0.000 title claims description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 81
- 150000003839 salts Chemical class 0.000 claims abstract description 25
- 102000003622 TRPC4 Human genes 0.000 claims abstract description 24
- 101150099990 Trpc4 gene Proteins 0.000 claims abstract description 24
- 101100100680 Schizosaccharomyces pombe (strain 972 / ATCC 24843) trp4 gene Proteins 0.000 claims abstract description 23
- 239000003112 inhibitor Substances 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 17
- 210000002510 keratinocyte Anatomy 0.000 claims abstract description 16
- 208000017520 skin disease Diseases 0.000 claims abstract description 10
- 210000003491 skin Anatomy 0.000 claims description 30
- 125000005843 halogen group Chemical group 0.000 claims description 20
- 125000001424 substituent group Chemical group 0.000 claims description 17
- 201000004681 Psoriasis Diseases 0.000 claims description 16
- 101150042815 TRPC5 gene Proteins 0.000 claims description 14
- 102000003621 TRPC5 Human genes 0.000 claims description 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- 206010020649 Hyperkeratosis Diseases 0.000 claims description 6
- 208000001126 Keratosis Diseases 0.000 claims description 6
- 125000005842 heteroatom Chemical group 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 230000000699 topical effect Effects 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 125000001072 heteroaryl group Chemical group 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 4
- 230000002159 abnormal effect Effects 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 4
- 206010021198 ichthyosis Diseases 0.000 claims description 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 2
- 230000005856 abnormality Effects 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- -1 pyrimidinedione compound Chemical class 0.000 abstract description 24
- 231100000915 pathological change Toxicity 0.000 abstract description 3
- 230000036285 pathological change Effects 0.000 abstract description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 189
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 112
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 96
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 78
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 69
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 68
- 239000012071 phase Substances 0.000 description 66
- 238000006243 chemical reaction Methods 0.000 description 65
- 239000000047 product Substances 0.000 description 64
- 238000005160 1H NMR spectroscopy Methods 0.000 description 59
- 238000001704 evaporation Methods 0.000 description 54
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 50
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 48
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 44
- 239000000243 solution Substances 0.000 description 43
- 238000004809 thin layer chromatography Methods 0.000 description 42
- 239000007787 solid Substances 0.000 description 40
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 35
- 210000004027 cell Anatomy 0.000 description 32
- 238000001816 cooling Methods 0.000 description 31
- 238000001914 filtration Methods 0.000 description 31
- 239000007858 starting material Substances 0.000 description 30
- 239000012043 crude product Substances 0.000 description 29
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 28
- 239000000741 silica gel Substances 0.000 description 28
- 229910002027 silica gel Inorganic materials 0.000 description 28
- 230000015572 biosynthetic process Effects 0.000 description 27
- 239000000706 filtrate Substances 0.000 description 26
- 239000002994 raw material Substances 0.000 description 26
- 238000003786 synthesis reaction Methods 0.000 description 26
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 25
- 229910052757 nitrogen Inorganic materials 0.000 description 25
- 238000001308 synthesis method Methods 0.000 description 25
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 24
- 239000000203 mixture Substances 0.000 description 24
- 238000004262 preparative liquid chromatography Methods 0.000 description 24
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 23
- 241000699670 Mus sp. Species 0.000 description 23
- 238000000034 method Methods 0.000 description 22
- 239000002904 solvent Substances 0.000 description 22
- 101150003085 Pdcl gene Proteins 0.000 description 20
- 239000000126 substance Substances 0.000 description 20
- 238000007865 diluting Methods 0.000 description 18
- 235000015110 jellies Nutrition 0.000 description 15
- 239000008274 jelly Substances 0.000 description 15
- 229920006395 saturated elastomer Polymers 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 238000010898 silica gel chromatography Methods 0.000 description 14
- 239000006071 cream Substances 0.000 description 13
- 239000012074 organic phase Substances 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- PPWNCLVNXGCGAF-UHFFFAOYSA-N 3,3-dimethylbut-1-yne Chemical compound CC(C)(C)C#C PPWNCLVNXGCGAF-UHFFFAOYSA-N 0.000 description 11
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 11
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 11
- 238000001035 drying Methods 0.000 description 11
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- GACOFEKSDCOVMV-UHFFFAOYSA-N (+)-englerin A Natural products O1C2(C(C)C)CC(OC(=O)CO)C1(C)C1CCC(C)C1C2OC(=O)C=CC1=CC=CC=C1 GACOFEKSDCOVMV-UHFFFAOYSA-N 0.000 description 9
- GCUOLJOTJRUDIZ-UHFFFAOYSA-N 2-(2-bromoethoxy)oxane Chemical compound BrCCOC1CCCCO1 GCUOLJOTJRUDIZ-UHFFFAOYSA-N 0.000 description 9
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 9
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 9
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- GACOFEKSDCOVMV-OWMMDXGCSA-N englerin A Natural products CC(C)[C@@]12C[C@@H](OC(=O)CO)[C@@](C)(O1)[C@@H]3CC[C@H](C)[C@@H]3[C@H]2OC(=O)C=Cc4ccccc4 GACOFEKSDCOVMV-OWMMDXGCSA-N 0.000 description 9
- GACOFEKSDCOVMV-RRYXBOBMSA-N englerin A Chemical compound O([C@H]1[C@@H]2[C@H](C)CC[C@H]2[C@@]2(C)[C@H](OC(=O)CO)C[C@@]1(O2)C(C)C)C(=O)\C=C\C1=CC=CC=C1 GACOFEKSDCOVMV-RRYXBOBMSA-N 0.000 description 9
- 210000002615 epidermis Anatomy 0.000 description 9
- 230000006872 improvement Effects 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- PRJHEJGMSOBHTO-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-1-(3-hydroxypropyl)-3-methyl-8-[3-(trifluoromethoxy)phenoxy]purine-2,6-dione Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)N(CCCO)C(=O)N(C)C=2N=C1OC1=CC=CC(OC(F)(F)F)=C1 PRJHEJGMSOBHTO-UHFFFAOYSA-N 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- KQNBRMUBPRGXSL-UHFFFAOYSA-N 1-(bromomethyl)-4-chlorobenzene Chemical compound ClC1=CC=C(CBr)C=C1 KQNBRMUBPRGXSL-UHFFFAOYSA-N 0.000 description 7
- 206010015150 Erythema Diseases 0.000 description 7
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 7
- 239000000460 chlorine Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 231100000321 erythema Toxicity 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 6
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- GKPOMITUDGXOSB-UHFFFAOYSA-N but-3-yn-2-ol Chemical compound CC(O)C#C GKPOMITUDGXOSB-UHFFFAOYSA-N 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 230000008595 infiltration Effects 0.000 description 6
- 238000001764 infiltration Methods 0.000 description 6
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- 230000008719 thickening Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- HJNHUFQGDJLQRS-UHFFFAOYSA-N 2-(3-bromopropoxy)oxane Chemical compound BrCCCOC1CCCCO1 HJNHUFQGDJLQRS-UHFFFAOYSA-N 0.000 description 5
- UZOFELREXGAFOI-UHFFFAOYSA-N 4-methylpiperidine Chemical compound CC1CCNCC1 UZOFELREXGAFOI-UHFFFAOYSA-N 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 230000003833 cell viability Effects 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 5
- 210000001853 liver microsome Anatomy 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 5
- XXFUZSHTIOFGNV-UHFFFAOYSA-N 1-bromoprop-1-yne Chemical compound CC#CBr XXFUZSHTIOFGNV-UHFFFAOYSA-N 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- YORLKVKBZRVNMZ-UHFFFAOYSA-N 4-bromobutoxy-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCCCCBr YORLKVKBZRVNMZ-UHFFFAOYSA-N 0.000 description 4
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- 238000003477 Sonogashira cross-coupling reaction Methods 0.000 description 4
- 102000027549 TRPC Human genes 0.000 description 4
- 108060008648 TRPC Proteins 0.000 description 4
- 235000011054 acetic acid Nutrition 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 230000008034 disappearance Effects 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 210000004969 inflammatory cell Anatomy 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 108090000862 Ion Channels Proteins 0.000 description 3
- 102000004310 Ion Channels Human genes 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 102000003627 TRPC1 Human genes 0.000 description 3
- 101150017559 TRPC1 gene Proteins 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- TXVJSWLZYQMWPC-UHFFFAOYSA-N ethynylcyclopentane Chemical group C#CC1CCCC1 TXVJSWLZYQMWPC-UHFFFAOYSA-N 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000003292 kidney cell Anatomy 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- 235000006408 oxalic acid Nutrition 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000005694 sulfonylation reaction Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- QSILYWCNPOLKPN-UHFFFAOYSA-N 3-chloro-3-methylbut-1-yne Chemical compound CC(C)(Cl)C#C QSILYWCNPOLKPN-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- UEXCJVNBTNXOEH-UHFFFAOYSA-N Ethynylbenzene Chemical group C#CC1=CC=CC=C1 UEXCJVNBTNXOEH-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 101100426589 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) trp-3 gene Proteins 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 206010033554 Palmoplantar keratoderma Diseases 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 102000003629 TRPC3 Human genes 0.000 description 2
- 102000003623 TRPC6 Human genes 0.000 description 2
- 102000003564 TRPC7 Human genes 0.000 description 2
- 101150095096 TRPM2 gene Proteins 0.000 description 2
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 108050001421 Transient receptor potential channel, canonical 6 Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 101150037542 Trpc3 gene Proteins 0.000 description 2
- 101150033973 Trpc7 gene Proteins 0.000 description 2
- HWSDRAPTZRYXHN-AATRIKPKSA-N [(e)-2-(4-chlorophenyl)ethenyl]boronic acid Chemical compound OB(O)\C=C\C1=CC=C(Cl)C=C1 HWSDRAPTZRYXHN-AATRIKPKSA-N 0.000 description 2
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- AEILLAXRDHDKDY-UHFFFAOYSA-N bromomethylcyclopropane Chemical compound BrCC1CC1 AEILLAXRDHDKDY-UHFFFAOYSA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000007810 chemical reaction solvent Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000003209 gene knockout Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 238000005658 halogenation reaction Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000010224 hepatic metabolism Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 229960002751 imiquimod Drugs 0.000 description 2
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 230000003228 microsomal effect Effects 0.000 description 2
- 229960001664 mometasone Drugs 0.000 description 2
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 2
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical group O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 201000008743 palmoplantar keratosis Diseases 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000008250 pharmaceutical cream Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 229920002554 vinyl polymer Chemical group 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- UFCSSWZQROEFBZ-UHFFFAOYSA-N 1-(bromomethyl)-4-chloro-2-fluorobenzene Chemical compound FC1=CC(Cl)=CC=C1CBr UFCSSWZQROEFBZ-UHFFFAOYSA-N 0.000 description 1
- NVNPLEPBDPJYRZ-UHFFFAOYSA-N 1-(bromomethyl)-4-fluorobenzene Chemical compound FC1=CC=C(CBr)C=C1 NVNPLEPBDPJYRZ-UHFFFAOYSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical group ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- CEVMYGZHEJSOHZ-UHFFFAOYSA-N 1-bromo-3-methoxypropane Chemical compound COCCCBr CEVMYGZHEJSOHZ-UHFFFAOYSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- QXSWHQGIEKUBAS-UHFFFAOYSA-N 1-ethynyl-4-fluorobenzene Chemical compound FC1=CC=C(C#C)C=C1 QXSWHQGIEKUBAS-UHFFFAOYSA-N 0.000 description 1
- KJNCIYYNPLWHDW-UHFFFAOYSA-N 1-ethynyladamantane Chemical compound C1C(C2)CC3CC2CC1(C#C)C3 KJNCIYYNPLWHDW-UHFFFAOYSA-N 0.000 description 1
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical compound OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 description 1
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 1
- LWISLHRIEATKTM-UHFFFAOYSA-N 2-Ethynylthiophene Chemical compound C#CC1=CC=CS1 LWISLHRIEATKTM-UHFFFAOYSA-N 0.000 description 1
- FCWYPDPDAZGFRJ-BQYQJAHWSA-N 2-[(e)-2-cyclopropylethenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1\C=C\C1CC1 FCWYPDPDAZGFRJ-BQYQJAHWSA-N 0.000 description 1
- NHUBNHMFXQNNMV-UHFFFAOYSA-N 2-ethynylpyridine Chemical compound C#CC1=CC=CC=N1 NHUBNHMFXQNNMV-UHFFFAOYSA-N 0.000 description 1
- CEBKHWWANWSNTI-UHFFFAOYSA-N 2-methylbut-3-yn-2-ol Chemical compound CC(C)(O)C#C CEBKHWWANWSNTI-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- JVSJDKRMKRFRBT-UHFFFAOYSA-N 2-prop-2-ynoxypropan-1-ol Chemical compound OCC(C)OCC#C JVSJDKRMKRFRBT-UHFFFAOYSA-N 0.000 description 1
- RKATWUBDSJHPEV-UHFFFAOYSA-N 3,3-difluorocyclobutan-1-amine Chemical compound NC1CC(F)(F)C1 RKATWUBDSJHPEV-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- YACFFSVYSPMSGS-UHFFFAOYSA-N 3-methoxyprop-1-yne Chemical compound COCC#C YACFFSVYSPMSGS-UHFFFAOYSA-N 0.000 description 1
- IMIHEZMTQOARIK-CMDGGOBGSA-N 4,4,5,5-tetramethyl-2-[(e)-pent-1-enyl]-1,3,2-dioxaborolane Chemical compound CCC\C=C\B1OC(C)(C)C(C)(C)O1 IMIHEZMTQOARIK-CMDGGOBGSA-N 0.000 description 1
- JJIFTOPVKWDHJI-UHFFFAOYSA-N 4-(bromomethyl)-1,2-difluorobenzene Chemical compound FC1=CC=C(CBr)C=C1F JJIFTOPVKWDHJI-UHFFFAOYSA-N 0.000 description 1
- CNUYBEIHDWMLSD-UHFFFAOYSA-N 4-(bromomethyl)-1-chloro-2-fluorobenzene Chemical compound FC1=CC(CBr)=CC=C1Cl CNUYBEIHDWMLSD-UHFFFAOYSA-N 0.000 description 1
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- OXRWICUICBZVAE-UHFFFAOYSA-N 4-methylpent-1-yne Chemical compound CC(C)CC#C OXRWICUICBZVAE-UHFFFAOYSA-N 0.000 description 1
- PKUFNWPSFCOSLU-UHFFFAOYSA-N 6-chloro-1h-pyrimidine-2,4-dione Chemical compound ClC1=CC(=O)NC(=O)N1 PKUFNWPSFCOSLU-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QTEQVEJOXGBDGI-UHFFFAOYSA-N 8-bromo-3-methyl-7h-purine-2,6-dione Chemical compound O=C1NC(=O)N(C)C2=C1NC(Br)=N2 QTEQVEJOXGBDGI-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 108091005462 Cation channels Proteins 0.000 description 1
- 102000034573 Channels Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- IVDFJHOHABJVEH-UHFFFAOYSA-N HOCMe2CMe2OH Natural products CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108060008646 TRPA Proteins 0.000 description 1
- 102000027545 TRPM Human genes 0.000 description 1
- 108091008847 TRPM Proteins 0.000 description 1
- 102000027544 TRPML Human genes 0.000 description 1
- 108091008846 TRPML Proteins 0.000 description 1
- 108060009332 TRPP Proteins 0.000 description 1
- 108060008564 TRPV Proteins 0.000 description 1
- 102000003563 TRPV Human genes 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000004012 Tofacitinib Substances 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000007488 abnormal function Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012445 acidic reagent Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 210000004727 amygdala Anatomy 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- UNXISIRQWPTTSN-UHFFFAOYSA-N boron;2,3-dimethylbutane-2,3-diol Chemical compound [B].[B].CC(C)(O)C(C)(C)O UNXISIRQWPTTSN-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- BRTFVKHPEHKBQF-UHFFFAOYSA-N bromocyclopentane Chemical compound BrC1CCCC1 BRTFVKHPEHKBQF-UHFFFAOYSA-N 0.000 description 1
- FLHFTXCMKFVKRP-UHFFFAOYSA-N bromomethylcyclobutane Chemical compound BrCC1CCC1 FLHFTXCMKFVKRP-UHFFFAOYSA-N 0.000 description 1
- 229950004398 broxuridine Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229940046731 calcineurin inhibitors Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229960002842 clobetasol Drugs 0.000 description 1
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- KTHXBEHDVMTNOH-UHFFFAOYSA-N cyclobutanol Chemical compound OC1CCC1 KTHXBEHDVMTNOH-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 1
- XCIXKGXIYUWCLL-UHFFFAOYSA-N cyclopentanol Chemical compound OC1CCCC1 XCIXKGXIYUWCLL-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- SSDZYLQUYMOSAK-UHFFFAOYSA-N ethynylcyclohexane Chemical group C#CC1CCCCC1 SSDZYLQUYMOSAK-UHFFFAOYSA-N 0.000 description 1
- NPTDXPDGUHAFKC-UHFFFAOYSA-N ethynylcyclopropane Chemical group C#CC1CC1 NPTDXPDGUHAFKC-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960001347 fluocinolone acetonide Drugs 0.000 description 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 210000005153 frontal cortex Anatomy 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000001282 glomerular podocyte Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- LVKCSZQWLOVUGB-UHFFFAOYSA-M magnesium;propane;bromide Chemical compound [Mg+2].[Br-].C[CH-]C LVKCSZQWLOVUGB-UHFFFAOYSA-M 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 229960002744 mometasone furoate Drugs 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000002353 niosome Substances 0.000 description 1
- LIENCHBZNNMNKG-OJFNHCPVSA-N nirmatrelvir Chemical compound CC1([C@@H]2[C@H]1[C@H](N(C2)C(=O)[C@H](C(C)(C)C)NC(=O)C(F)(F)F)C(=O)N[C@@H](C[C@@H]3CCNC3=O)C#N)C LIENCHBZNNMNKG-OJFNHCPVSA-N 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- YWWARDMVSMPOLR-UHFFFAOYSA-M oxolane;tetrabutylazanium;fluoride Chemical compound [F-].C1CCOC1.CCCC[N+](CCCC)(CCCC)CCCC YWWARDMVSMPOLR-UHFFFAOYSA-M 0.000 description 1
- 230000037324 pain perception Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 210000005223 peripheral sensory neuron Anatomy 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 description 1
- 229960005330 pimecrolimus Drugs 0.000 description 1
- 210000000557 podocyte Anatomy 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- UARFKZSJGDQRLF-UHFFFAOYSA-N prop-2-ynylcyclohexane Chemical compound C#CCC1CCCCC1 UARFKZSJGDQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000037075 skin appearance Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- KKVTYAVXTDIPAP-UHFFFAOYSA-M sodium;methanesulfonate Chemical compound [Na+].CS([O-])(=O)=O KKVTYAVXTDIPAP-UHFFFAOYSA-M 0.000 description 1
- 239000002047 solid lipid nanoparticle Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 230000006103 sulfonylation Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical compound C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 229960001350 tofacitinib Drugs 0.000 description 1
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 1
- 238000002723 toxicity assay Methods 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- HQYNSFAFYFMRLG-UHFFFAOYSA-N tribromo phosphite Chemical compound BrOP(OBr)OBr HQYNSFAFYFMRLG-UHFFFAOYSA-N 0.000 description 1
- YFDSDPIBEUFTMI-UHFFFAOYSA-N tribromoethanol Chemical compound OCC(Br)(Br)Br YFDSDPIBEUFTMI-UHFFFAOYSA-N 0.000 description 1
- 229950004616 tribromoethanol Drugs 0.000 description 1
- CWLNAJYDRSIKJS-UHFFFAOYSA-N triethoxymethoxyethane Chemical compound CCOC(OCC)(OCC)OCC CWLNAJYDRSIKJS-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a condensed pyrimidinedione compound and pharmaceutically acceptable salts thereof, the structural formula of the compound is shown as formula (I),the compound and the pharmaceutically acceptable salt thereof can be used as a TRPC4/5 inhibitor and for preparing a medicament for treating skin diseases related to keratinocyte pathological changes.
Description
Technical Field
The invention relates to the field of pharmaceutical chemistry, in particular to a fused pyrimidinedione compound, and application and a pharmaceutical composition thereof.
Background
Transient Receptor Potential (TRP) ion channels are six-time transmembrane channel proteins widely distributed in the peripheral and central nervous systems, and are molecular receptors for sensing environmental changes of cells, transmitting signals and maintaining cell homeostasis. Mammalian TRP ion channels can be divided into six subfamilies of TRPA, TRPC, TRPM, TRPML, TRPP, TRPV, etc. according to sequence similarity. The classical Transient Receptor Potential (TRPC) channel is a non-selective cation channel, allowing Ca 2+ 、Na + And (4) permeating. The mammal TRPC consists of six members of TRPC1, TRPC3, TRPC4, TRPC5, TRPC6 and TRPC7, wherein the amino acid sequence of the TRPC3, the TRPC6 and the TRPC7 has higher consistency, and the sequence of the TRPC1, the TRPC4 and the TRPC5 has higher consistency. TRP family proteins exist in a homozygous or heterotetrameric form and exert an ion channel effect, and TRPC5 is easy to form a heterotetramer with TRPC1 and TRPC4 (J Med chem.2019,62, 7589.).
TRPC4/5 is expressed in a plurality of parts in brain, including hippocampus, amygdala, frontal cortex and the like, and is related to the occurrence of central nervous system diseases such as anxiety, depression, epilepsy, addiction and the like. The TRPC4 or TRPC5 gene knockout, or the application of TPRC4/5 inhibitor can relieve anxiety and depression symptoms in mice (PLoS ONE.2018,13, e0191225.). Recent studies have found that TRPC5 is also expressed in glomerular podocytes, and its dysfunction is linked to the development of chronic kidney disease. TRPC5 gene knock-out or application of TPRC5 inhibitor can reduce proteinuria, protect podocyte, and inhibit renal disease progression (science.2017, 358, 1332.). The prior art is studied for inhibitors of TRPC4/5, for example, patent applications WO2014143799, WO2019011802 disclose xanthine TRPC4/5 inhibitors, and patent applications WO2019055966, WO2020061162 disclose pyridazinone TRPC4/5 inhibitors.
TRPC4 and TRPC5 are expressed in skin keratinocytes and peripheral sensory neurons, and play an important role in regulating keratinocyte differentiation and pain perception (Pharmaceuticals (Basel). Keratinocytes are the major component of the epidermal layer of the skin, which not only constitute the natural barrier of the skin against physical, chemical and biological invasion, but also participate in the initiation of the skin's immune inflammatory response. Abnormal differentiation and proliferation of keratinocytes lead to the formation of keratoderma manifested as skin keratinosis, dry and cracked skin, scaling, itching, etc. Keratoderma is divided into hereditary and acquired types, and mainly comprises ichthyosis, palmoplantar keratosis, olmsted disease, toad skin disease, menopausal keratoderma and the like. Psoriasis is a common chronic inflammatory skin disease characterized by excessive immune cell infiltration and abnormal keratinocyte differentiation, proliferation in the dermis and epidermis. There is increasing evidence that keratinocyte dysfunction is an important factor in the development, progression and recurrence of psoriasis, and thus targeted modulation of keratinocytes is a new option for treating psoriasis (J Leukoc biol.2020,108, 485). No published reports have been made on the use of TRPC4/5 inhibitors and drugs containing the inhibitor components and capable of targeted regulation of keratinocytes.
Disclosure of Invention
The invention discloses an 8-site ethynyl or vinyl substituted condensed pyrimidinedione compound which can be used as a TRPC4/5 inhibitor and used for preparing a compound for treating skin diseases related to keratinocyte pathological changes. Compared with the prior TRPC4/5 inhibitor, the compound disclosed by the invention has higher in vitro activity and faster liver microsome metabolism rate. When the compound is used for preparing a skin external medicament, the compound can be rapidly cleared by liver metabolism after being absorbed through skin. Since TRPC4 and TRPC5 are widely distributed in human physiological tissue structures and also play an important role in maintaining normal physiological functions, rapidly metabolized TRPC4/5 inhibitors can avoid systemic side effects to a greater extent.
The technical scheme adopted by the invention is as follows:
condensed pyrimidinedione compounds and pharmaceutically acceptable salts thereof, wherein the structural formula of the compounds is shown as formula (I),
wherein R is 1 Is C 1 -C 6 Alkyl groups of (a);
each R is 2 Independently a halogen atom;
R 3 selected from substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 3 -C 10 Substituted or unsubstituted 6-to 10-membered aryl and substituted or unsubstituted 5-to 8-membered heteroaryl, wherein R 3 The substituent(s) is 1 to 3 groups selected from the group consisting of: c 1 -C 6 Alkyl of (C) 3 -C 8 Cycloalkyl of (ii), -OR 4 、-N(R 4 ) 2 And a halogen atom;
each R 4 Each independently selected from H, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 3 -C 8 Cycloalkyl, substituted or unsubstituted phenyl, wherein R 4 The substituents of (a) are 1 to 3 groups of the following group: c 3 -C 8 Cycloalkyl, halogen atom, hydroxyl and = O; or,
two R 4 Taken together to form a 4-to 8-membered substituted or unsubstituted heterocyclic ring, the heteroatoms of which are selected from N, O, and S and contain at least 1N, the number of heteroatoms being 1 or 2; the substituents of the heterocycle are 1-3 groups independently selected from the group consisting of: c 1 -C 6 Alkyl groups and halogen atoms of (a);
n is an integer of 1 to 3;
x is N or CH;
y is selected from one of ethynyl and substituted or unsubstituted vinyl, of which vinylThe substituent is 1-2C 1 -C 6 An alkyl group.
As a further improvement of the technical scheme, R 1 Is methyl, ethyl or isopropyl.
As a further improvement of the technical scheme, R 3 Is C 3 -C 10 Cycloalkyl OR-OR of 4 、-N(R 4 ) 2 Substituted C 1 -C 6 Alkyl group of (1).
As a further improvement of the technical solution, said compound is selected from the structural formulae (II a) to (IIc):
wherein,
R 1 is methyl, ethyl or isopropyl;
each R 2 Each independently a halogen atom;
ring C is substituted or unsubstituted C 3 -C 10 Substituted or unsubstituted phenyl or substituted or unsubstituted 5-to 8-membered heteroaryl, wherein the substituents of ring C are 1 to 3 groups selected from: c 1 -C 6 Alkyl groups and halogen atoms of (a);
R 4 each independently selected from substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 3 -C 8 A cycloalkyl group, a substituted or unsubstituted phenyl group of (a), wherein R 4 The substituent(s) is 1 to 3 groups selected from the group consisting of: c 3 -C 8 Cycloalkyl groups and halogen atoms of (a); or,
two R 4 Together with N to form a 4-to 8-membered substituted or unsubstituted heterocycle having 1 to 3C substituents 1 -C 6 Alkyl groups of (a);
R 5 、R 6 each independently is H or C 1 -C 3 Alkyl groups of (a);
n is an integer of 1 to 3.
As a further improvement in the technical solution, said compound is selected from the group consisting of:
unless otherwise indicated, the terms used in the present invention have the following definitions:
in the present invention, unless otherwise specified, the terms used have the ordinary meanings well known to those skilled in the art.
In the present invention, the term "C1-C3" means having 1, 2 or 3 carbon atoms, the term "C1-C6" means having 1, 2,3, 4, 5 or 6 carbon atoms, and so on. "4-8 membered" means having 4, 5, 6,7 or 8 ring atoms, and so on.
In the present invention, the "alkyl group" is a branched and straight chain hydrocarbon group having a specific number of carbon atoms, and representative examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, tert-butyl, and the like.
In the present invention, the "haloalkyl group" means a group in which a hydrogen atom in an "alkyl group" having a specific number of carbon atoms is partially or completely substituted with a "halogen atom".
In the present invention, the "cycloalkyl" represents a non-aromatic cyclic aliphatic hydrocarbon group having a specific number of ring-forming carbon atoms, and includes monocyclic, fused, bridged, and spiro ring systems. Representative examples are, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, decahydronaphthyl, adamantyl, and the like.
In the present invention, "aryl" is defined as monocyclic and bicyclic ring systems consisting of a specified number of carbon atoms and complying with Huckel's rule, including but not limited to benzene, naphthalene rings.
In the present invention, "heteroaryl" is defined as monocyclic and bicyclic ring systems having a specified number of ring members and containing 1, 2,3 or 4 heteroatoms (selected from N, O, S) while complying with the huckel rule, including but not limited to pyridine, pyrrole, imidazole, thiophene.
In the present invention, "heterocycle" is defined as a saturated or partially unsaturated non-aromatic cyclic group consisting of a specified number of ring-forming atoms, and contains 1, 2,3 or 4 hetero atoms (selected from N, O, S) as ring-forming atoms, and the others are carbon atoms. Examples of heterocycles include, but are not limited to, morpholine, piperazine, piperidine, pyrrolidine, and the like.
In the present invention, the "halogen atom" includes 4 atoms of fluorine, chlorine, bromine and iodine.
The term "substituted" as used herein means substituted with one or more groups. If it is not specified that it occurs at a particular atom, it is meant that it may occur at any atom for which the number of substituents has not yet reached saturation.
The term "independently" as used herein means that when a plurality of substituents are selected from the same group, they may be the same or different.
The "pharmaceutically acceptable salts" of the present invention may be salts of anions with positively charged groups on the compounds of formula (I). Suitable anions are chloride, bromide, iodide, sulfate, nitrate, phosphate, citrate, methylsulfonate, trifluoroacetate, acetate, malate, tosylate, tartrate, fumarate, glutamate, glucuronate, lactate, glutarate or maleate. Similarly, salts may be formed from cations with negatively charged groups on the compounds of formula (I). Suitable cations include sodium, potassium, magnesium, calcium, and ammonium ions, such as tetramethylammonium. Preferably, "pharmaceutically acceptable salt" refers to a salt of a compound of formula (I) with an acid selected from the group consisting of: hydrofluoric acid, hydrochloric acid, hydrobromic acid, phosphoric acid, acetic acid, oxalic acid, sulfuric acid, nitric acid, methanesulfonic acid, sulfamic acid, salicylic acid, trifluoromethanesulfonic acid, naphthalenesulfonic acid, maleic acid, citric acid, acetic acid, lactic acid, tartaric acid, succinic acid, oxalic acid, pyruvic acid, malic acid, glutamic acid, p-toluenesulfonic acid, naphthalenesulfonic acid, ethanesulfonic acid, naphthalenedisulfonic acid, malonic acid, fumaric acid, propionic acid, oxalic acid, trifluoroacetic acid, stearic acid, pamoic acid, hydroxymaleic acid, phenylacetic acid, benzoic acid, glutamic acid, ascorbic acid, p-aminobenzenesulfonic acid, 2-acetoxybenzoic acid, isethionic acid and the like.
The compound of the general formula (I) or the pharmaceutically acceptable salt thereof is distilled out, crystallized or recrystallized from water or an organic solvent, and the compound may contain solvent molecules used. In addition, different crystallization conditions may result in different crystalline forms of the compound. Therefore, the compound shown in the general formula (I) or the pharmaceutically acceptable salt thereof containing different chemical doses of crystallization solvents and all crystal forms are within the scope of the invention.
In the present invention, some compounds are asymmetric, e.g., having one or more stereogenic centers, with an olefinic bond. Unless otherwise indicated, the present invention is intended to include all stereo, optical and geometric isomers, such as, but not limited to, enantiomers, diastereomers, racemates, E/Z isomers, as well as mixtures of the individual isomers in varying proportions, and pharmaceutically acceptable salts thereof. Compounds of the present invention containing asymmetrically substituted carbon atoms may be isolated in optically active, racemic or cis-trans isomeric forms.
In the present invention, the "effective therapeutic dose" means that a subject treated with the dose is cured, improved, effectively prevented from suffering from a disease, a side effect, or the like, or the incidence thereof is significantly reduced, as compared with a subject not treated with the dose; in addition, it includes an effective amount to enhance normal physiological function.
It is another object of the present invention to provide a process for the preparation of a compound of formula (I), said process being selected from scheme 1 or 2;
the reaction procedure of scheme 1 is shown in formula A:
wherein PG represents a hydroxyl protecting group such as, but not limited to, tetrahydropyran (THP), tert-butyldimethylsilyl (TBDMS), 2-trimethylsilylethoxymethyl (SEM); halo is a halogen atom; the other substituents are as defined above for formula (I);
the reaction steps of scheme 1 include:
(1.1) intermediate INT-A1 (see WO2014143799 Synthesis) with acetylenic starting Material(purchased commercially or synthesized according to literature procedures) to undergo a Sonogashira coupling reaction to produce the intermediate INT-A2;
the Sonogashira coupling reaction is usually carried out under the action of a palladium catalyst, a copper salt and an organic base; such as but not limited to PdCl 2 (Ph 3 P) 2 、PdCl 2 (dppf)、Pd(Ph 3 P) 4 (ii) a Such as, but not limited to, cuI, cuBr; such as, but not limited to triethylamine, N-Diisopropylethylamine (DIPEA); the reaction is carried out in an excess of organic base or with the addition of a suitable amount of organic solvent, such as N, N-Dimethylformamide (DMF); the reaction temperature is generally between room temperature and 80 ℃; the reaction conditions can be suitably adjusted by those skilled in the art based on literature or actual conditions encountered during the synthetic process;
(1.2) removing a protecting group of the intermediate INT-A2 to generate a compound shown in a general formula (I); the deprotection reaction of the hydroxyl group is usually carried out under the action of an acidic reagent or a fluorine ion reagent; such as, but not limited to, trifluoroacetic acid, hydrogen chloride, p-toluenesulfonic acid; such as, but not limited to, tetrabutylammonium fluoride, KF, HF;
(1.3) in another alternative, the intermediate INT-A1 may be prepared by first removing the hydroxy protecting group to form intermediate INT-A3, and then reacting with an acetylenic starting materialCarrying out Sonogashira coupling reaction to generate a compound shown in a general formula (I); the reaction conditions are the same as those of the steps (1) and (2);
scheme 2 applies to compounds of general formulae (II B) and (II c) according to the reaction scheme shown in formula B:
wherein L is a leaving group including sulfonate and halogen atoms such as, but not limited to, mesylate, triflate, p-tosylate, chlorine atom, bromine atom, iodine atom; PG, halo are as defined above for formula A; the other substituents are as defined above for the general formulae (II b) and (II c);
the reaction steps of scheme 2 include:
(2.1) intermediate INT-A1 (synthesized with reference to WO 2014143799) with acetylenic starting material(purchased commercially or synthesized according to literature procedures) to undergo a Sonogashira coupling reaction to produce an intermediate INT-B1; the reaction conditions are the same as in the reaction step (1.1);
(2.2) carrying out sulfonylation reaction or halogenation reaction on the intermediate INT-B1 to generate an intermediate INT-B2; the sulfonylation reaction is carried out by a sulfonylation reagent under the action of a base; such sulfonylating agents as, but not limited to, methanesulfonyl chloride, trifluoromethanesulfonic anhydride, p-toluenesulfonyl chloride; the base includes organic bases such as but not limited to triethylamine, DIPEA, p-Dimethylaminopyridine (DMAP) and inorganic bases such as but not limited to K 2 CO 3 、Cs 2 CO 3 (ii) a The halogenation reaction is carried out under the action of a halogenating agent; such as, but not limited to, thionyl chloride, phosphorus tribromide, I 2 /Ph 3 P, etc.; the reaction solvent is typically an aprotic solvent such as, but not limited to, dichloromethane, tetrahydrofuran; the reaction temperature is generally from-20 ℃ to room temperature;
(2.3) intermediate INT-B2 with HOR 4 Substitution reaction is carried out to generate an intermediate INT-B3 or an intermediate INT-B2 and HN (R) 4 ) 2 Carrying out substitution reaction to generate an intermediate INT-B4; the substitution reaction is carried out under the action of alkali; the base comprisesOrganic bases such as but not limited to triethylamine, DIPEA, DMAP and inorganic bases such as but not limited to K 2 CO 3 、Cs 2 CO 3 NaH; the reaction solvent is typically a polar solvent such as, but not limited to, tetrahydrofuran, acetonitrile, DMF; the reaction temperature is generally 0 ℃ to 80 ℃;
(2.4) deprotecting the intermediate INT-B3 or INT-B4 to produce a compound of formula (II B) or formula (II c); the reaction conditions were the same as in the aforementioned reaction step (1.2).
The invention also discloses an application of the compound or the pharmaceutically acceptable salt thereof, and the compound or the pharmaceutically acceptable salt thereof is used as a TRPC4 and TRPC5 inhibitor or is used for preparing a medicament for treating diseases related to abnormal function and expression of TRPC4 or/and TRPC 5.
In the invention, the compound shown in the general formula (I), the salt thereof and the pharmaceutical composition thereof can be used in combination with other drugs with action mechanisms when being used for treating skin diseases; such as, but not limited to, glucocorticoid based drugs, such as mometasone, fluocinolone acetonide, triamcinolone acetonide, hydrocortisone, clobetasol, and the like; janus kinase inhibitors such as lucentitinib, tofacitinib, uppatinib, and the like; calcineurin inhibitors such as tacrolimus, pimecrolimus; biological immunomodulators, such as adalimumab, infliximab, etanercept, etc.
In the present invention, the compound of formula (I) is usually used in the form of a pharmaceutical composition for the preparation of a medicament, which comprises one or more therapeutically effective amounts of the compound of formula (I) and one or more pharmaceutical excipients; the pharmaceutic adjuvant is a pharmaceutically acceptable carrier, an excipient, a sustained release agent, a flavoring agent and the like.
In the pharmaceutical composition, the compound shown in the general formula (I) is used as an active component, the weight of the compound accounts for 0.1-99.9% of the total weight of the pharmaceutical composition, and the balance is pharmaceutically acceptable auxiliary materials; the compound shown in the general formula (I) and pharmaceutically acceptable auxiliary materials are preferably mixed in a proportion that the compound shown in the general formula (I) as an active ingredient accounts for more than 60 percent of the total weight, the rest accounts for 0 to 40 percent of the total weight, and the amount of the rest is preferably 1 to 20 percent, and most preferably 1 to 10 percent.
The compounds and pharmaceutical compositions provided herein can be formulated into a variety of dosage forms based on procedures customary in the pharmaceutical formulation art, such as tablets, capsules, powders, syrups, solutions, suspensions, sprays, creams, ointments, gels, transdermal patches, and the like, and can be in a suitable solid or liquid carrier or diluent. The pharmaceutical compositions of the present invention may also be stored in a suitable injection or drip sterilization device.
As a further improvement of the technical solution, the pharmaceutical composition is used for treating skin diseases associated with keratinocyte abnormalities.
As a further improvement of the technical solution, the disease is psoriasis, ichthyosis, palmoplantar keratosis, olmsted's disease, toad's skin disease or menopausal keratoderma.
The compound shown in the general formula (I) or the pharmaceutical composition containing the compound shown in the general formula (I) can be clinically used for mammals including human and animals, and the administration route can comprise oral administration, nasal cavity inhalation, skin local administration, lung administration, gastrointestinal tract administration and the like. The preferred route of administration is topical application to the skin. In the present invention, topical application means applying the drug to a body surface, such as skin or mucous membranes.
When the compound shown in the general formula (I) or the pharmaceutical composition thereof is used for preparing skin topical application, the compound can be prepared into a suitable pharmaceutical dosage form, such as but not limited to cream, ointment, gel, transdermal patch, spray and the like. The drug carrier can be selected from starch, oil, cream, foam, ointment, skin lotion, gel, etc., and can also be drug delivery system, such as liposome, niosome, microsponge, microemulsion, microsphere, solid lipid nanoparticle, etc.
When used as a pharmaceutical formulation, the compounds of formula (I) of the present invention may be effectively dissolved, suspended or dispersed in a liquid medium to form a solution, suspension or dispersion for topical application to the skin by application or spraying, and may be delivered as an aid in a sponge, patch, pad or other cosmetic device. In some cases, a slow release delivery system for a compound may be important to exert drug efficacy.
When used as a pharmaceutical preparation, the compound represented by the general formula (I) of the present invention is preferably used in a unit dose, each dose containing 0.01mg to 200mg, preferably 0.5mg to 50mg of the active ingredient, once or in divided portions. Regardless of the method of administration, the optimal dosage for an individual will depend on the particular treatment. Usually, the dosage is increased gradually starting from a small dosage until the most suitable dosage is found.
Compared with the prior art, the fused pyrimidinedione compound and the pharmaceutically acceptable salt thereof have outstanding substantive characteristics and remarkable progress, and particularly can be used as a TRPC4/5 inhibitor or for preparing a medicine for treating skin diseases related to keratinocyte pathological changes. Further, the compounds disclosed herein have higher in vitro activity and faster rate of liver microsome metabolism compared to existing TRPC4/5 inhibitors. Furthermore, when the compound is used for preparing a skin external medicament, the compound can be rapidly metabolized and cleared by the liver after being absorbed by the skin, and systemic side effects are avoided.
Description of the drawings:
FIG. 1 is a graph showing the effect of compound E37 on the inhibition of IL-17-induced proliferation of human immortalized keratinocytes HaCaT and the quantitative results.
Figure 2 is a graph of the improvement in the appearance of psoriasis induced by imiquimod by the cream with compound E37 as active ingredient.
FIG. 3 is a graph showing the effect of the cream containing the compound E37 as an active ingredient on the improvement of the dorsal skin disease of mice induced by imiquimod and the quantitative results.
DETAILED DESCRIPTION OF EMBODIMENT (S) OF INVENTION
The invention will be further illustrated by the following examples. It is specifically noted that these examples are only intended to illustrate the invention and do not limit it in any way. All parameters in the examples and the remaining description are based on mass unless otherwise stated. If not, all the fillers used for column chromatography are silica gel. Experimental procedures without specific conditions noted in the following examples, generally according to conventional conditions, or according to conditions recommended by the manufacturer.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. In addition, any methods and materials similar or equivalent to those described herein can be used in the practice of the present invention. The preferred embodiments and materials described herein are exemplary only.
Abbreviations: DCM: dichloromethane; DIPEA: n, N-diisopropylethylamine; DMAP: 4-dimethylaminopyridine; DMF: n, N-dimethylformamide; DMSO, DMSO: dimethyl sulfoxide; TBAF: tetrabutylammonium fluoride; TFA: trifluoroacetic acid; THF: and (4) tetrahydrofuran.
Example E1- (4-chlorobenzyl) -1- (3-hydroxypropyl) -8- (3-methoxyprop-1-yn-1-yl) -3-methyl-3, 7-dihydro-1H-purine-2, 6-dione
The starting material INT 1-1 was synthesized according to the method described in patent application WO 2014143799. INT 1-1 (43mg, 0.1mmol), pdCl 2 (Ph 3 P) 2 (10.5mg, 0.015mmol), cuI (5.7mg, 0.03mmol), 1.5mL of triethylamine, and 0.5mL of DMF were placed in a pressure-resistant tube, degassed with nitrogen for 3min, then 3-methoxy-1-propyne (42. Mu.L, 0.5 mmol) was added, and further degassed for 0.5min. The pressure tube was sealed and heated at 60 ℃ for 6h. After cooling, diluting with ethyl acetate, filtering to remove insoluble substances, and evaporating the filtrate under reduced pressure to obtain a crude product. Then, the mixture was purified by preparative liquid chromatography (C18 packing), eluted with acetonitrile/water system as mobile phase, and the target product fraction was collected and evaporated to dryness to obtain 20mg of white solid. 1 H-NMR(500MHz,Chloroform-d)δ7.41(d,J=8.5Hz,2H),7.34(d,J=8.5Hz,2H),5.59(s,2H),4.45(s,2H),4.20(t,J=4.0Hz,2H),3.60(s,3H),3.54(m,2H),3.49(s,3H),3.37(brs,1H),1.91(m,2H);MS(ESI):m/z417.1[M+H] + .
Example E2- (4-chlorobenzyl) -8- (3-cyclobutoxyprop-1-yn-1-yl) -1- (3-hydroxypropyl) -3-methyl-3, 7-dihydro-1H-purine-2, 6-dione
Sodium hydride (60% in oil, 1.44g, 36mmol) was suspended in 20mL dry THF, cyclobutanol (2g, 27.78mmol) was added dropwise to the reaction mixture, the gas was evolved and dropped over 5min, and stirring was continued for 0.5h. Bromopropyne (2.63mL, 30.5 mmol) was then added dropwise over 5min and heated at 50 ℃ for 4h. TLC showed disappearance of the starting material, after cooling, the reaction was quenched by dropping 2mL of saturated ammonium chloride solution and drying with anhydrous magnesium sulfate. After 1h, the inorganic salts were removed by filtration, washed with THF, and THF was added to about 28mL to give a 1mol/L THF solution of intermediate INT 2-1.
Intermediate INT 2-2 was synthesized according to the method described in patent application WO 2014143799.
INT 2-2(102mg,0.2mmol)、PdCl 2 (Ph 3 P) 2 (21mg, 0.03mmol), cuI (11.4mg, 0.06mmol), triethylamine 3mL, and DMF 1mL were placed in a pressure tube, degassed with nitrogen for 3min, then intermediate INT 2-1 (1mL, 1mmol) was added, and further degassed for 1min. The pressure tube was sealed and heated at 60 ℃ for 4h. After cooling, diluting with ethyl acetate, filtering to remove insoluble substances, and evaporating the filtrate under reduced pressure to obtain a crude product. And separating by using a flash silica gel chromatographic column, eluting by using MeOH/DCM as a mobile phase, collecting a target product part, and evaporating to dryness to obtain 86mg of white solid, namely the intermediate INT 2-3.
Intermediate INT 2-3 (86mg, 0.16mmol) was dissolved in 2mL DCM, then 0.4mL TFA was added, stirred at RT for 1h, TLC indicated complete reaction. The solvent was evaporated under reduced pressure and the residue was purified by preparative liquid chromatography (C18 packing) eluting with acetonitrile/water system as the mobile phase, the target product fraction was collected and evaporated to dryness to give 42mg of a white solid, example E2. 1 H-NMR(500MHz,Chloroform-d)δ7.40(d,J=8.5Hz,2H),7.33(d,J=8.5Hz,2H),5.59(s,2H),4.39(s,2H),4.20(t,J=4.0Hz,2H),4.15(m,1H),3.59(s,3H),3.54(m,2H),3.33(brs,1H),2.26(m,2H),2.01(m,2H),1.76(m,1H),1.57(m,1H);MS(ESI):m/z 457.2[M+H] + .
Example E3- (4-chlorobenzyl) -8- (3-cyclobutoxyprop-1-yn-1-yl) -1- (2-hydroxyethyl) -3-methyl-3, 7-dihydro-1H-purine-2, 6-dione
8-bromo-3-methyl-3, 7-dihydro-1H-purine-2, 6-dione (244mg, 1mmol) was dissolved in 10mL of DMF, and KHCO was added 3 (150mg, 1.5 mmol) and 4-chlorobenzyl bromide (204mg, 1mmol) at 60 ℃ for 3 hours. After TLC detection, insoluble matter was removed by filtration, and the mixture was partitioned with ethyl acetate/saturated aqueous NaCl solution to separate an organic phase, dried over anhydrous sodium sulfate and then separated by flash silica gel chromatography, eluted with MeOH/DCM as a mobile phase, and the target product fraction, intermediate INT3-1, was collected as about 330mg.
INT3-1 (330mg, 0.89mmol) described above was dissolved in DMF and K was added 2 CO 3 (249mg, 1.8mmol), and then 2- (2-bromoethoxy) tetrahydro-2H-pyran (225mg, 1.08mmol) was added thereto, followed by reaction at 60 ℃ for 6 hours. After cooling, the mixture was partitioned with ethyl acetate/saturated aqueous NaCl, the organic phase was separated, dried over anhydrous sodium sulfate and separated by flash chromatography on silica gel to give the intermediate INT3-2 of about 400mg.
The synthesis method of the intermediate INT 3-3 is the same as INT 2-3, except that the intermediate INT3-2 is used for replacing INT 2-2 as a raw material.
Example E3 was synthesized according to the same method as E2, except that INT 2-3 was replaced by INT 3-3 as the starting intermediate.
H-NMR(500MHz,DMSO-d6)δ7.50–7.41(m,2H),7.36–7.30(m,2H),5.57(s,2H),4.76(t,J=6.0Hz,1H),4.40(s,2H),4.04–3.98(m,1H),3.96(t,J=6.5Hz,2H),3.52(q,J=6.5Hz,2H),3.41(s,3H),2.16–2.07(m,2H),1.84(ttd,J=10.0,7.9,2.8Hz,2H),1.68–1.58(m,1H),1.45(qt,J=10.5,8.0Hz,1H).MS(ESI):m/z 443.1[M+H] + .
Example E4- (4-chlorobenzyl) -8- (3-cyclobutoxyprop-1-yn-1-yl) -1- (4-hydroxybutyl) -3-methyl-3, 7-dihydro-1H-purine-2, 6-dione
The synthesis method of the intermediate INT 4-1 is the same as INT3-2 except that (4-bromobutoxy) (tert-butyl) dimethylsilane is used as a raw material instead of 2- (2-bromoethoxy) tetrahydro-2H-pyran.
The synthesis method of the intermediate INT 4-2 is the same as INT 2-3, except that the intermediate INT 4-1 is used for replacing INT 2-2 as a raw material.
Intermediate INT 4-2 (117mg, 0.2mmol) was dissolved in 8mL THF, then 1mol/L TBAF tetrahydrofuran solution was added dropwise at room temperature, stirred at room temperature for 1h, TLC indicated completion of the reaction. Saturated NH 4 The solution was quenched with aqueous Cl, extracted 2 times with ethyl acetate, washed 1 time with saturated aqueous NaCl and dried over anhydrous magnesium sulfate. Filtering, evaporating to obtain crude product, purifying with preparative liquid chromatography column (C18 filler), eluting with acetonitrile/water system as mobile phase, collecting target product part, and evaporating to obtain 55mg white solid as example E4. 1 H-NMR(600MHz,DMSO-d6)δ7.43(d,J=8.4Hz,2H),7.31(d,J=8.4Hz,2H),5.56(s,2H),4.39(s,2H),4.38(t,J=5.7Hz,1H),3.99(p,J=7.3Hz,1H),3.86(t,J=7.4Hz,2H),3.42–3.36(m,5H),2.10(dtt,J=9.4,7.2,2.6Hz,2H),1.84(dtd,J=12.5,10.0,7.9Hz,2H),1.66–1.59(m,1H),1.55(td,J=8.1,5.7Hz,2H),1.45–1.37(m,3H).MS(ESI):m/z 471.2[M+H] + .
Example E5- (3-Cyclobutoxyprop-1-yn-1-yl) -7- (4-fluorobenzyl) -1- (2-hydroxyethyl) -3-methyl-3, 7-dihydro-1H-purine-2, 6-dione
The intermediate INT 5-1 was synthesized in the same manner as INT3-1 except that 4-fluorobenzyl bromide was used instead of 4-chlorobenzyl bromide.
The intermediate INT 5-2 is synthesized by the same method as INT3-2 except that INT3-1 is replaced by the intermediate INT 5-1.
The synthesis method of the intermediate INT 5-3 is the same as INT 2-3, except that the intermediate INT 5-2 is used for replacing INT 2-2 as a raw material.
Example E5 was synthesized according to the same method as E2, except that INT 2-3 was replaced by INT 5-3 as the starting intermediate. 1 H-NMR(500MHz,DMSO-d6)δ7.42–7.35(m,2H),7.24–7.17(m,2H),5.56(s,2H),4.76(t,J=6.0Hz,1H),4.42(s,2H),4.08–4.00(m,1H),3.97(t,J=6.6Hz,2H),3.52(q,J=6.5Hz,2H),3.41(s,3H),2.13(dddd,J=10.6,6.8,5.2,2.5Hz,2H),1.86(dddd,J=19.3,10.0,7.9,2.8Hz,2H),1.69–1.58(m,1H),1.45(qt,J=10.5,8.0Hz,1H).MS(ESI):m/z 427.2[M+H] + .
EXAMPLE E6- (3-Cyclobutoxyprop-1-yn-1-yl) -7- (4-fluorobenzyl) -1- (3-hydroxypropyl) -3-methyl-3, 7-dihydro-1H-purine-2, 6-dione
The synthesis method of the intermediate INT 6-1 is the same as INT3-2, except that INT 5-1 is used for replacing INT3-1, and 2- (3-bromopropoxy) tetrahydro-2H-pyran is used for replacing 2- (2-bromoethoxy) tetrahydro-2H-pyran as a raw material.
The synthesis method of the intermediate INT 6-2 is the same as INT 2-3, except that the intermediate INT 6-1 is used for replacing INT 2-2 as a raw material.
Example E6 was synthesized according to the same method as E2, except that INT 2-3 was replaced by INT 6-2, an intermediate, as a starting material. 1 H-NMR(500MHz,DMSO-d6)δ7.360~7.387(m,2H),7.178~7.213(m,2H),5.546(s,2H),4.447~4.467(t,J=5Hz,1H),4.408(s,2H),3.997~4.055(m,1H),3.902~3.932(t,J=7Hz,2H),3.413~3.449(q,J=6Hz,2H),3.397(s,3H),2.093~2.150(m,2H),1.810~1.869(m,2H),1.671~1.712(m,2H),1.414~1.468(m,2H).MS(ESI):m/z 441.2[M+H] + .
Example E7- (3-Cyclobutoxyprop-1-yn-1-yl) -7- (4-fluorobenzyl) -1- (4-hydroxybutyl) -3-methyl-3, 7-dihydro-1H-purine-2, 6-dione
The synthesis method of the intermediate INT 7-1 is the same as INT3-2, except that INT3-1 is replaced by the intermediate INT 5-1, and 2- (2-bromoethoxy) tetrahydro-2H-pyran is replaced by (4-bromobutoxy) (tert-butyl) dimethylsilane as a raw material.
The synthesis method of the intermediate INT 7-2 is the same as INT 2-3, except that the intermediate INT 7-1 is used for replacing INT 2-2 as a raw material.
The synthesis of example E7 was performed as in E4, except that INT 4-2 was replaced by INT 7-2 as the starting material. 1 H-NMR(600MHz,DMSO-d6)δ7.40–7.32(m,2H),7.19(t,J=8.8Hz,2H),5.55(s,2H),4.41(s,2H),4.38(t,J=5.2Hz,1H),4.03(p,J=7.3Hz,1H),3.86(t,J=7.4Hz,2H),3.39(m,5H),2.12(dddd,J=11.1,9.4,6.9,2.5Hz,2H),1.85(dtd,J=12.5,10.2,8.0Hz,2H),1.66–1.59(m,1H),1.59–1.52(m,2H),1.47–1.37(m,3H).MS(ESI):m/z 455.2[M+H] + .
Example E8- (3-Cyclobutoxyprop-1-yn-1-yl) -7- (3, 4-difluorobenzyl) -1- (2-hydroxyethyl) -3-methyl-3, 7-dihydro-1H-purine-2, 6-dione
The intermediate INT 8-1 was synthesized in the same manner as INT3-1 except that 3, 4-difluorobenzyl bromide was used as the starting material instead of 4-chlorobenzyl bromide.
The synthesis method of the intermediate INT 8-2 is the same as INT3-2, except that the intermediate INT 8-1 is used as a raw material to replace INT 3-1.
The synthesis method of the intermediate INT 8-3 is the same as INT 2-3, except that the intermediate INT 8-2 is used for replacing INT 2-2 as a raw material.
Example E8 was synthesized according to the same method as E2, except that INT 2-3 was replaced by INT 8-3 as the starting intermediate. 1 H-NMR(600MHz,DMSO-d6)δ7.48–7.37(m,2H),7.18–7.11(m,1H),5.56(s,2H),4.74(t,J=6.0Hz,1H),4.40(s,2H),4.05–3.99(m,1H),3.96(t,J=6.6Hz,2H),3.52(q,J=6.5Hz,2H),3.40(s,3H),2.12(dtt,J=11.5,6.9,2.5Hz,2H),1.84(ttd,J=10.0,7.8,2.8Hz,2H),1.67–1.58(m,1H),1.48–1.41(m,1H).MS(ESI):m/z 445.2[M+H] + .
Example E9- (3-Cyclobutoxyprop-1-yn-1-yl) -7- (3, 4-difluorobenzyl) -1- (3-hydroxypropyl) -3-methyl-3, 7-dihydro-1H-purine-2, 6-dione
The synthesis method of the intermediate INT 9-1 is the same as INT3-2, except that the intermediate INT 8-1 is used for replacing INT3-1, and 2- (3-bromopropoxy) tetrahydro-2H-pyran is used for replacing 2- (2-bromoethoxy) tetrahydro-2H-pyran as a raw material.
The synthesis method of the intermediate INT 9-2 is the same as INT 2-3, except that the intermediate INT 9-1 is used as a raw material to replace INT 2-2.
Example E9 was synthesized according to the same method as E2, except that INT 2-3 was replaced by INT 9-2, an intermediate, as a starting material. 1 H-NMR(600MHz,DMSO-d6)δ7.48–7.37(m,2H),7.14(m,1H),5.55(s,2H),4.45(t,J=5.3Hz,1H),4.40(s,2H),4.01(p,J=7.2Hz,1H),3.92(t,J=6.0,H),3.43(q,J=6.1Hz,2H),3.40(s,3H),2.15–2.08(m,2H),1.84(m,2H),1.72–1.66(m,2H),1.66–1.58(m,1H),1.44(m,J 1H);MS(ESI):m/z 459.2[M+H] + .
Example E10- (3-Cyclobutoxyprop-1-yn-1-yl) -7- (3, 4-difluorobenzyl) -1- (4-hydroxybutyl) -3-methyl-3, 7-dihydro-1H-purine-2, 6-dione
The synthesis method of the intermediate INT 10-1 is the same as INT3-2, except that the intermediate INT 8-1 is used for replacing INT3-1, and (4-bromobutoxy) (tert-butyl) dimethyl silane is used for replacing 2- (2-bromoethoxy) tetrahydro-2H-pyran as a raw material.
The synthesis method of the intermediate INT 10-2 is the same as INT 2-3, except that the intermediate INT 10-1 is used for replacing INT 2-2 as a raw material.
The synthesis of example E10 is the same as E4, except that INT 4-2 is replaced by the intermediate INT 10-2. 1 H-NMR(600MHz,DMSO-d6)δ7.47–7.37(m,2H),7.14(ddd,J=9.8,4.6,2.2Hz,1H),5.55(s,2H),4.40(s,2H),4.38(t,J=5.2Hz,1H),4.01(p,J=7.3Hz,1H),3.87(t,J=7.4Hz,2H),3.42–3.36(m,5H),2.11(ddt,J=14.7,6.9,2.5Hz,2H),1.89–1.80(m,2H),1.66–1.60(m,1H),1.59–1.53(m,2H),1.47–1.38(m,3H).MS(ESI):m/z 473.2[M+H] + .
Example E11- (4-chloro-2-fluorobenzyl) -8- (3-cyclobutoxyprop-1-yn-1-yl) -1- (2-hydroxyethyl) -3-methyl-3, 7-dihydro-1H-purine-2, 6-dione
The synthesis method of the intermediate INT 11-1 is the same as INT3-1, except that 4-chloro-2-fluorobenzyl bromide is used as a raw material instead of 4-chlorobenzyl bromide.
The synthesis method of the intermediate INT 11-2 is the same as INT3-2, except that the intermediate INT 11-1 is used as a raw material to replace INT 3-1.
The synthesis method of the intermediate INT 11-3 is the same as INT 2-3, except that the intermediate INT 11-2 is used for replacing INT 2-2 as a raw material.
Example E11 was synthesized according to the same method as E2, except that INT 2-3 was replaced by INT 11-3 as the starting intermediate. 1 H-NMR(600MHz,DMSO-d6)δ7.52(dd,J=10.1,2.0Hz,1H),7.26(dd,J=8.3,2.0Hz,1H),7.09(t,J=8.2Hz,1H),5.61(s,2H),4.73(t,J=5.9Hz,1H),4.34(s,2H),3.95(m,3H),3.49(q,J=6.4Hz,2H),3.41(s,3H),2.08(dtd,J=11.7,7.5,6.2,2.6Hz,2H),1.82(dq,J=13.2,10.1Hz,2H),1.61(q,J=10.1Hz,1H),1.43(dtd,J=18.5,10.5,8.1Hz,1H).MS(ESI):m/z 461.1[M+H] + .
Example E12- (4-chloro-2-fluorobenzyl) -8- (3-cyclobutoxyprop-1-yn-1-yl) -1- (3-hydroxypropyl) -3-methyl-3, 7-dihydro-1H-purine-2, 6-dione
The synthesis method of the intermediate INT 12-1 is the same as INT3-2, except that the intermediate INT 11-1 is used for replacing INT3-1, and 2- (3-bromopropoxy) tetrahydro-2H-pyran is used for replacing 2- (2-bromoethoxy) tetrahydro-2H-pyran as a raw material.
INT 12-1(100mg,0.1894mmol)、PdCl 2 (Ph 3 P) 2 (19.9mg, 0.0284mmol), cuI (10.8mg, 0.0568mmol), triethylamine 3mL and DMF 1mL were placed in a pressure-resistant tube, degassed with nitrogen for 3min, then intermediate INT 2-1 (0.95mL, 0.95mmol) was added and degassed for 1min. The pressure tube was sealed and heated at 60 ℃ for 4h. Cooling, diluting with ethyl acetate, filtering to remove insoluble substances, and evaporating the filtrate under reduced pressure to obtain crude extractAnd (5) preparing the product. And separating by using a flash silica gel chromatographic column, eluting by using MeOH/DCM as a mobile phase, collecting a target product part, and evaporating to dryness to obtain 86mg of a white solid, namely the intermediate INT12-2.
Intermediate INT12-2 (84mg, 0.15mmol) was dissolved in 2mL DCM, then 0.4mL TFA was added, stirred at room temperature for 1h, TLC indicated complete reaction. The solvent was evaporated under reduced pressure and the residue was purified by preparative liquid chromatography using acetonitrile/water system as mobile phase, the target product fraction was collected and evaporated to dryness to obtain 41mg of white solid, example E12. 1 H-NMR(600MHz,DMSO-d6)δ7.52(dd,J=10.1,2.1Hz,1H),7.26(dd,J=8.2,2.1Hz,1H),7.09(t,J=8.3Hz,1H),5.61(s,2H),4.44(t,J=5.2Hz,1H),4.34(s,2H),3.96(p,J=7.3Hz,1H),3.89(m,t,J=6.5Hz,2H),3.41(m,5H),2.12–2.04(m,2H),1.82(dtd,J=12.7,10.2,7.9Hz,2H),1.67(p,J=6.5Hz,2H),1.63–1.57(m,1H),1.43(qt,J=10.5,8.0Hz,1H);(ESI):m/z 475.2[M+H] + .
Example E13- (4-chloro-2-fluorobenzyl) -8- (3-cyclobutoxyprop-1-yn-1-yl) -1- (4-hydroxybutyl) -3-methyl-3, 7-dihydro-1H-purine-2, 6-dione
The synthesis method of the intermediate INT 13-1 is the same as INT3-2, except that the intermediate INT 11-1 is used for replacing INT3-1, and (4-bromobutoxy) (tert-butyl) dimethyl silane is used for replacing 2- (2-bromoethoxy) tetrahydro-2H-pyran as a raw material.
INT 13-1(100mg,0.175mmol)、PdCl 2 (Ph 3 P) 2 (18.4mg, 0.0263mmol), cuI (10mg, 0.0526mmol), 3mL of triethylamine and 1mL of DMF were placed in a pressure-resistant tube, degassed with nitrogen for 3min, then intermediate INT 2-1 (0.9mL, 0.9mmol) was added, and further degassed for 1min. The pressure tube was sealed and heated at 60 ℃ for 4h. After cooling, diluting with ethyl acetate, filtering to remove insoluble substances, and evaporating the filtrate under reduced pressure to obtain a crude product. And separating by using a flash silica gel chromatographic column, eluting by using MeOH/DCM as a mobile phase, collecting a target product part, and evaporating to dryness to obtain 90mg of a white solid, namely the intermediate INT13-2.
The synthesis of example E13 was performed as in E4, except that INT13-2 was used as the starting material instead of INT 4-2. 53mg of example E13, white solid, were obtained from 90mg of intermediate INT13-2. 1 H-NMR(600MHz,DMSO-d6)δ7.51(dd,J=10.1,2.1Hz,1H),7.26(dd,J=8.4,2.1Hz,1H),7.08(t,J=8.3Hz,1H),5.61(s,2H),4.38(t,J=5.2Hz,1H),4.34(s,2H),4.00–3.92(m,1H),3.84(t,J=7.4Hz,2H),3.42(s,3H),3.38(td,J=6.4,5.0Hz,2H),2.08(ddt,J=14.6,6.8,2.5Hz,2H),1.81(qdd,J=10.2,5.0,2.2Hz,2H),1.65–1.58(m,1H),1.57–1.50(m,2H),1.41(dddd,J=21.9,15.8,11.8,7.3Hz,3H).MS(ESI):m/z 489.2[M+H] + .
Example E14- (4-chloro-3-fluorobenzyl) -8- (3-cyclobutoxyprop-1-yn-1-yl) -1- (2-hydroxyethyl) -3-methyl-3, 7-dihydro-1H-purine-2, 6-dione
The intermediate INT 14-1 was synthesized in the same manner as INT3-1 except that 4-chloro-3-fluorobenzyl bromide was used instead of 4-chlorobenzyl bromide.
The synthesis method of the intermediate INT 14-2 is the same as INT3-2, except that the intermediate INT 14-1 is used for replacing INT3-1 as a raw material.
The synthesis method of the intermediate INT 14-3 is the same as INT 2-3, except that the intermediate INT 14-2 is used for replacing INT 2-2 as a raw material.
Example E14 was synthesized according to the same method as E2, except that INT 2-3 was replaced by INT 14-3 as the starting intermediate. 1 H-NMR(600MHz,DMSO-d6)δ7.59(t,J=8.0Hz,1H),7.36(dd,J=10.0,2.0Hz,1H),7.12(d,J=8.4Hz,1H),5.58(s,2H),4.73(t,J=6.0Hz,1H),4.38(s,2H),3.96(m,3H),3.51(q,J=6.5Hz,2H),3.41(s,3H),2.13–2.05(m,2H),1.87–1.78(m,2H),1.61(q,J=10.3Hz,1H),1.43(dtd,J=18.4,10.4,7.9Hz,1H).MS(ESI):m/z 461.1[M+H] + .
Example E15- (4-chloro-3-fluorobenzyl) -8- (3-cyclobutoxyprop-1-yn-1-yl) -1- (3-hydroxypropyl) -3-methyl-3, 7-dihydro-1H-purine-2, 6-dione
The synthesis method of the intermediate INT 15-1 is the same as INT3-2, except that the intermediate INT 14-1 is used for replacing INT3-1, and 2- (3-bromopropoxy) tetrahydro-2H-pyran is used for replacing 2- (2-bromoethoxy) tetrahydro-2H-pyran as a raw material.
INT 15-1(100mg,0.1893mmol)、PdCl 2 (Ph 3 P) 2 (19.9mg, 0.0284mmol), cuI (10.8mg, 0.0568mmol), triethylamine 3mL and DMF 1mL were placed in a pressure-resistant tube, degassed with nitrogen for 3min, then intermediate INT 2-1 (0.95mL, 0.95mmol) was added and degassed for 1min. The pressure tube was sealed and heated at 60 ℃ for 4h. After cooling, diluting with ethyl acetate, filtering to remove insoluble substances, and evaporating the filtrate under reduced pressure to obtain a crude product. And separating by using a flash silica gel chromatographic column, eluting by using MeOH/DCM as a mobile phase, collecting a target product part, and evaporating to dryness to obtain 81mg of a white solid, namely the intermediate INT15-2.
Intermediate INT15-2 (81mg, 0.145mmol) was dissolved in 2mL DCM, then 0.4mL TFA was added, stirred at RT for 1h and TLC indicated completion of the reaction. The solvent was evaporated under reduced pressure and the residue was purified by preparative liquid chromatography using acetonitrile/water system as mobile phase, the target product fraction was collected and evaporated to dryness to give 39mg of white solid as example E15. 1 H-NMR(500MHz,Chloroform-d)δ7.40(t,J=8.0Hz,1H),7.26(d,J=9.4Hz,1H),7.22(d,J=8.4Hz,1H),5.58(s,2H),4.39(s,2H),4.21(t,J=6.0Hz,2H),4.15(t,J=7.3Hz,1H),3.60(s,3H),3.56(t,J=5.5Hz,2H),2.26(t,J=7.8Hz,3H),2.05–2.00(m,2H),1.93(m,2H),1.67(m,1H),1.61–1.52(m,1H).MS(ESI):m/z 475.2[M+H] + .
Example E16- (4-chlorobenzyl) -8- (3-cyclobutoxyprop-1-yn-1-yl) -1- (3-hydroxypropyl) -3-isopropyl-3, 7-dihydro-1H-purine-2, 6-dione
2,6-dihydroxypurine (15g, 0.0987mol) was suspended in 240mL of water, and 7.5mL of liquid bromine (0.1464 mol) was added dropwise at room temperature, and after completion of the dropwise addition, the reaction was allowed to proceed overnight at 100 ℃. After cooling to room temperature, the solid was filtered, washed several times with distilled water and dried to give the intermediate INT 16-1.
Intermediate INT 16-1 (2.3 g, 10mmol) was dissolved in DMSO, and KHCO was added 3 (1.2g, 12mmol), 4-chlorobenzyl bromide (2.04g, 10mmol) was further added, and the mixture was reacted at 35 ℃ overnight. The reaction solution was poured into a saturated aqueous NaCl solution, extracted 3 times with ethyl acetate, the organic phases were combined, and washed 3 times with a saturated aqueous NaCl solution. Anhydrous MgSO (MgSO) 4 And (3) drying, separating by using a flash silica gel chromatographic column, eluting by using MeOH/DCM as a mobile phase, and collecting a target product part to obtain an intermediate INT 16-2.
Intermediate INT 16-2 (2.48g, 7mmol) was dissolved in DMF and K was added 2 CO 3 (1.16g, 8.4 mmol) and iodoisopropane (1.19g, 7 mmol) were reacted at 40 ℃ overnight. The reaction solution was poured into a saturated aqueous NaCl solution, extracted 3 times with ethyl acetate, and the organic phases were combined and washed 3 times with a saturated aqueous NaCl solution. Anhydrous MgSO (MgSO) 4 And (3) drying, separating by using a flash silica gel chromatographic column, eluting by using MeOH/DCM as a mobile phase, and collecting a target product part to obtain an intermediate INT 16-3.
Intermediate INT 16-3 (1.386g, 3.5mmol) was dissolved in DMF and K was added 2 CO 3 (0.967 g,7 mmol) and 2- (3-bromopropoxy) tetrahydro-2H-pyran (0.932g, 4.2mmol) were reacted at 60 ℃ overnight. The reaction solution was then poured into a saturated aqueous NaCl solution, extracted 3 times with ethyl acetate, the organic phases were combined and washed 3 times with a saturated aqueous NaCl solution. Anhydrous MgSO (MgSO) 4 And (4) drying, separating by using a flash silica gel chromatographic column, eluting by using MeOH/DCM as a mobile phase, and collecting a target product part to obtain an intermediate INT 16-4.
INT 16-4(108mg,0.2mmol)、PdCl 2 (Ph 3 P) 2 (21mg, 0.03mmol), cuI (11.4mg, 0.06mmol), triethylamine 3mL and DMF 1mL were placed in a pressure resistant tube, degassed with nitrogen for 3min, then intermediate INT 2-1 (1mL, 1mmol) was added and degassed for 1min. The pressure tube was sealed and heated at 60 ℃ for 4h. After cooling, diluting with ethyl acetate, filtering to remove insoluble substances, and evaporating the filtrate under reduced pressure to obtain a crude product. Separating with flash silica gel chromatography column, eluting with MeOH/DCM as mobile phase, collecting target product, and evaporating to dryness to obtain 80mg of white solid, i.e. mediumIntermediate INT16-5.
Intermediate INT16-5 (80mg, 0.14mmol) was dissolved in 2mL DCM, then 0.4mL TFA was added, stirred at RT for 1h, TLC indicated complete reaction. The solvent was evaporated under reduced pressure and the residue was purified by preparative liquid chromatography using acetonitrile/water system as mobile phase, the target product fraction was collected and evaporated to dryness to obtain 40mg of white solid, example E16. 1 H-NMR(500MHz,DMSO-d6)δ7.48–7.42(m,2H),7.37–7.32(m,2H),5.57(s,2H),5.05(m,1H),4.47(t,J=5.2Hz,1H),4.41(s,2H),4.00(m,1H),3.92(t,J=7.5Hz,2H),3.44(q,J=6.1Hz,2H),2.17–2.07(m,2H),1.85(m,2H),1.69(m,2H),1.65–1.59(m,1H),1.49(d,J=7.0Hz,6H),1.47–1.39(m,1H);MS(ESI):m/z 485.2[M+H] + .
Example E17- (4-chlorobenzyl) -8- (3-cyclobutoxyprop-1-yn-1-yl) -3-ethyl-1- (3-hydroxypropyl) -3, 7-dihydro-1H-purine-2, 6-dione
The synthesis method of the intermediate INT 17-1 is the same as INT 16-3, except that iodoethane is used as a raw material to replace iodoisopropane.
The synthesis method of the intermediate INT 17-2 is the same as INT 16-4, except that the intermediate INT 17-1 is used for replacing INT 16-3 as a raw material.
The synthesis method of the intermediate INT 17-3 is the same as INT16-5, except that the intermediate INT 17-2 is used for replacing INT 16-4 as a raw material.
The synthesis of example E17 was performed as in E16, except that INT16-5 was replaced by INT 17-3 as the starting material. 1 H-NMR(500MHz,DMSO-d6)δ7.44(d,J=8.4Hz,2H),7.34(d,J=8.2Hz,2H),5.57(s,2H),4.48(t,J=5.2Hz,1H),4.40(s,2H),4.12(q,J=5.2Hz,1H),4.01(m,2H),3.93(t,J=7.0Hz,2H),3.44(q,J=6.1Hz,2H),2.12(m,2H),1.84(m,2H),1.69(m,2H),1.62(m,1H),1.45(m,1H),1.22(t,J=7.6Hz,3H);MS(ESI):m/z 471.2[M+H] +.
Example E18- (4-chlorobenzyl) -8- (3- (cyclopentyloxy) prop-1-yn-1-yl) -1- (3-hydroxypropyl) -3-methyl-3, 7-dihydro-1H-purine-2, 6-dione
Sodium hydride (60% in oil, 1.44g, 36mmol) was suspended in 20mL of dry THF, cyclopentanol (2.41g, 28mmol) was added dropwise to the reaction mixture, the gas evolved, and the reaction was stirred for an additional 0.5h over 5min. Bromopropyne (2.63mL, 30.5 mmol) was then added dropwise over 5min and heated at 50 ℃ for 4h. TLC showed disappearance of the starting material, and after cooling, the reaction was quenched by addition of 2mL of saturated ammonium chloride solution dropwise, and dried by addition of anhydrous magnesium sulfate. After 1h, the inorganic salts were removed by filtration, washed with THF, and THF was added to about 28mL to give a 1mol/L THF solution of intermediate INT 18-1.
INT 2-2(100mg,0.196mmol)、PdCl 2 (Ph 3 P) 2 (20.6mg, 0.0294mmol), cuI (11.17mg, 0.0588mmol), 3mL of triethylamine, and 1mL of DMF were placed in a pressure-resistant tube, degassed with nitrogen for 3min, then intermediate INT 18-1 (1mL, 1mmol) was added, and further degassed for 1min. The pressure pipe is sealed and heated for 4-6 h at 60 ℃. After cooling, the mixture was diluted with ethyl acetate, the insoluble matter was removed by filtration, and the filtrate was evaporated to dryness under reduced pressure to give a crude product. And separating by using a flash silica gel chromatographic column, eluting by using MeOH/DCM as a mobile phase, collecting a target product part, and evaporating to dryness to obtain 78mg of a white solid, namely the intermediate INT 18-2.
Intermediate INT 18-2 (78mg, 0.14mmol) was dissolved in 2mL DCM, then 0.4mL TFA was added, stirred at RT for 1h, TLC indicated complete reaction. The solvent was evaporated under reduced pressure and the residue was purified by preparative liquid chromatography using acetonitrile/water system as mobile phase, the target product fraction was collected and evaporated to dryness to obtain 32mg of white solid, example E18. 1 H-NMR(500MHz,DMSO-d6)δ7.43(d,J=8.5Hz,2H),7.32(d,J=8.2Hz,2H),5.57(s,2H),4.48(t,J=5.2Hz,1H),4.45(s,2H),4.02(m,1H),3.92(t,J=7.5Hz,2H),3.48–3.42(m,2H),3.41(s,3H),1.74–1.51(m,8H),1.47(m,2H);MS(ESI):m/z 471.2[M+H] + .
Example E19- (3- (cyclopentyloxy) prop-1-yn-1-yl) -7- (4-fluorobenzyl) -1- (3-hydroxypropyl) -3-methyl-3, 7-dihydro-1H-purine-2, 6-dione
Example E19 was synthesized according to the same method as E18, except that INT 2-2 was replaced with INT 6-1 as the starting intermediate. 1 H-NMR(500MHz,DMSO-d6)δ7.42–7.36(m,2H),7.23–7.16(m,2H),5.56(s,2H),4.47(m,3H),4.05(tt,J=5.8,2.9Hz,1H),3.96–3.90(m,2H),3.44(q,J=6.2Hz,2H),3.41(s,3H),1.74–1.54(m,8H),1.49(m,2H);MS(ESI):m/z 455.2[M+H] + .
Example E20- (4-chlorobenzyl) -8- (3- (cyclohexyloxy) prop-1-yn-1-yl) -1- (3-hydroxypropyl) -3-methyl-3, 7-dihydro-1H-purine-2, 6-dione
Sodium hydride (60% in oil, 1.44g, 36mmol) was suspended in 20mL of dry THF, cyclohexanol (2.8g, 27.78mmol) was added dropwise to the atmosphere, the gas evolved over 5min, and stirring was continued for an additional 0.5h. Bromopropyne (2.63mL, 30.5 mmol) was then added dropwise over 5min and heated at 50 ℃ for 4h. TLC showed disappearance of the starting material, after cooling, the reaction was quenched by dropping 2mL of saturated ammonium chloride solution and drying with anhydrous magnesium sulfate. After 1h, the inorganic salts were removed by filtration, washed with THF, and THF was added to about 28mL to give a 1mol/L THF solution of intermediate INT 20-1.
INT 2-2(100mg,0.196mmol)、PdCl 2 (Ph 3 P) 2 (20.6mg, 0.0294mmol), cuI (11.2mg, 0.0588mmol), 3mL of triethylamine, and 1mL of DMF were placed in a pressure-resistant tube, degassed with nitrogen for 3min, then intermediate INT 20-1 (1mL, 1mmol) was added, and further degassed for 1min. The pressure pipe is sealed and heated for 4-6 h at 60 ℃. After cooling, diluting with ethyl acetate, filtering to remove insoluble substances, and evaporating the filtrate under reduced pressure to obtain a crude product. And then separating by using a flash silica gel chromatographic column, eluting by using MeOH/DCM as a mobile phase, collecting a target product part, and evaporating to dryness to obtain 66mg of a white solid, namely an intermediate INT 20-2.
Intermediate INT 20-2 (66mg, 0.12mmol) was dissolved in 2mL DCM, then 0.4mL TFA was added, stirring at room temperature for 1h, TLC indicated complete reaction. The solvent was evaporated under reduced pressure and the residue was purified by preparative liquid chromatography using acetonitrile/water system as mobile phase, the target product fraction was collected and evaporated to dryness to give 30mg of white solid as example E20. 1 H-NMR(500MHz,DMSO-d6)δ7.43(d,J=8.3Hz,2H),7.32(d,J=8.2Hz,2H),5.56(s,2H),4.52(s,2H),4.47(t,J=5.2Hz,1H),3.92(t,J=7.4Hz,2H),3.48–3.36(m,6H),1.82(m,2H),1.72–1.65(m,2H),1.63(m,2H),1.46(m,1H),1.20(m,5H).MS(ESI):m/z 485.2[M+H] + .
Example E21- (3- (cyclohexyloxy) prop-1-yn-1-yl) -7- (4-fluorobenzyl) -1- (3-hydroxypropyl) -3-methyl-3, 7-dihydro-1H-purine-2, 6-dione
Example E21 was synthesized as in E20, except that INT 2-2 was replaced by INT 6-1, the intermediate. 1 H-NMR(500MHz,DMSO-d6)δ7.42–7.35(m,2H),7.23–7.16(m,2H),5.55(s,2H),4.54(s,2H),4.48(t,J=5.2Hz,1H),3.96–3.89(m,2H),3.47–3.42(m,2H),3.41(s,3H),1.86–1.80(m,2H),1.73–1.58(m,4H),1.49–1.43(m,1H),1.26–1.15(m,5H).MS(ESI):m/z 469.2[M+H] + .
Example E22- (3- (cyclohexyloxy) prop-1-yn-1-yl) -7- (3, 4-difluorobenzyl) -1- (3-hydroxypropyl) -3-methyl-3, 7-dihydro-1H-purine-2, 6-dione
The synthesis of example E22 was performed as in E20, except that INT 2-2 was replaced by INT 9-1 as the starting intermediate. 1 H-NMR(500MHz,DMSO-d6)δ7.48–7.37(m,2H),7.14(d,J=8.0Hz,1H),5.56(s,2H),4.52(s,2H),4.48(t,J=5.2Hz,1H),3.96–3.89(m,2H),3.43(m,5H),1.84–1.79(m,2H),1.69(m,2H),1.66–1.58(m,2H),1.46(m,1H),1.28–1.14(m,5H).MS(ESI):m/z 487.2[M+H] + .
Example E23- (4-chlorobenzyl) -8- (3- (cyclohexyloxy) prop-1-yn-1-yl) -1- (3-hydroxypropyl) -3-isopropyl-3, 7-dihydro-1H-purine-2, 6-dione
The synthesis of example E23 was performed as in E20, except that INT 2-2 was replaced by INT 16-4, an intermediate. 1 H-NMR(500MHz,DMSO-d6)δ7.46–7.41(m,2H),7.34(d,J=8.4Hz,2H),5.56(s,2H),5.04(m,1H),4.52(s,2H),4.48(t,J=5.2Hz,1H),3.94–3.88(m,2H),3.44(q,J=6.1Hz,2H),1.84–1.79(m,2H),1.72–1.65(m,2H),1.62(m,2H),1.49(d,J=6.0Hz,6H),1.46(m,1H),1.23–1.12(m,5H);MS(ESI):m/z 513.2[M+H] + .
Example E24- (4-chlorobenzyl) -8- (3-hydroxybut-1-yn-1-yl) -1- (3-hydroxypropyl) -3-methyl-3, 7-dihydro-1H-purine-2, 6-dione
INT 2-2(100mg,0.196mmol)、PdCl 2 (Ph 3 P) 2 (20.6mg, 0.0294mmol), cuI (11.17mg, 0.0588mmol), 3mL of triethylamine, and 1mL of DMF were placed in a pressure tube, degassed with nitrogen for 3min, then 3-butyn-2-ol (28mg, 0.4mmol) was added, and further degassed for 1min. The pressure pipe is sealed and heated for 4-6 h at 60 ℃. After cooling, diluting with ethyl acetate, filtering to remove insoluble substances, and evaporating the filtrate under reduced pressure to obtain a crude product. And separating by using a flash silica gel chromatographic column, eluting by using MeOH/DCM as a mobile phase, collecting a target product part, and evaporating to dryness to obtain 65mg of jelly, namely an intermediate INT 24-1.
Intermediate INT 24-1 (65mg, 0.13mmol) was dissolved in 2mL DCM, then 0.4mL TFA was added, stirred at RT for 1h, TLC indicated complete reaction. The solvent was evaporated under reduced pressure and the residue was purified by preparative liquid chromatography using acetonitrile/water system as mobile phase, the target product fraction was collected and evaporated to dryness to obtain 41mg of white solid, example E24. 1 H-NMR(500MHz,DMSO-d6)δ7.47–7.41(m,2H),7.38(d,J=8.6Hz,2H),5.82(d,J=5.6Hz,1H),5.54(s,2H),4.75–4.66(m,1H),4.48(t,J=5.2Hz,1H),3.96–3.89(m,2H),3.44(q,J=6.1Hz,2H),3.40(s,3H),1.74–1.65(m,2H),1.41(d,J=6.7Hz,3H).MS(ESI):m/z 417.1[M+H] + .
Example E25- (4-chlorobenzyl) -1- (3-hydroxypropyl) -3-methyl-8- (3-phenoxypropyl-1-yn-1-yl) -3, 7-dihydro-1H-purine-2, 6-dione
Phenol (2.64g, 30mmol) was dissolved in 20mL dry DMF and K was added 2 CO 3 (4.97g, 36mmol), stirring for 0.5h. Then, bromopropyne (2.63mL, 30.5 mmol) was added dropwise thereto over 5min, and the reaction was carried out at room temperature. TLC showed disappearance of the starting material, saturated brine was added, extraction was performed three times with ethyl acetate, and the organic layers were combined, washed three times with saturated brine, and dried over anhydrous sodium sulfate. Filtering, evaporating the filtrate under reduced pressure, and then diluting to 30mL with THF to obtain a THF solution with the concentration of the intermediate INT 25-1 being about 1 mol/L.
INT 2-2(100mg,0.196mmol)、PdCl 2 (Ph 3 P) 2 (20.6mg, 0.0294mmol), cuI (11.2mg, 0.0588mmol), 3mL of triethylamine, and 1mL of DMF were placed in a pressure-resistant tube, degassed with nitrogen for 3min, then intermediate INT 25-1 (1mL, 1mmol) was added, and further degassed for 1min. The pressure pipe is sealed and heated for 4-6 h at 60 ℃. After cooling, the mixture was diluted with ethyl acetate, the insoluble matter was removed by filtration, and the filtrate was evaporated to dryness under reduced pressure to give a crude product. And then separating by using a flash silica gel chromatographic column, eluting by using MeOH/DCM as a mobile phase, collecting a target product part, and evaporating to dryness to obtain 87mg of white solid, namely an intermediate INT 25-2.
Intermediate INT 25-2 (87mg, 0.159mmol) was dissolved in 2mL DCM, then 0.4mL TFA was added, stirred at room temperature for 1h, TLC indicated complete reaction. The solvent was evaporated under reduced pressure and the residue was purified by preparative liquid chromatography using acetonitrile/water system as the mobile phase, the target product fraction was collected and evaporated to dryness to obtain 40mg of white solid, example E25. 1 H-NMR(500MHz,DMSO-d6)δ7.38–7.30(m,4H),7.26(d,J=8.4Hz,2H),7.08–7.03(m,2H),7.01(t,J=7.3Hz,1H),5.48(s,2H),5.23(s,2H),4.48(t,J=5.2Hz,1H),3.94–3.86(m,2H),3.43(q,J=6.2Hz,2H),3.39(s,3H),1.73–1.64(m,2H).MS(ESI):m/z 479.1[M+H] + .
Example E26- (4-chlorobenzyl) -8- (3- ((1-hydroxypropyl-2-oxy) prop-1-yn-1-yl) -1- (3-hydroxypropyl) -3-methyl-3, 7-dihydro-1H-purine-2, 6-dione
Example E26 was synthesized as in E24, except that 2- (2-propyn-1-yloxy) propan-1-ol was used as starting material instead of 3-butyn-2-ol. 1 H-NMR(500MHz,DMSO-d6)δ7.43(d,J=8.2Hz,2H),7.35(d,J=8.2Hz,2H),5.56(s,2H),4.73(d,J=4.7Hz,1H),4.54(s,2H),4.48(t,J=5.2Hz,1H),3.97–3.87(m,2H),3.75(p,J=5.7Hz,1H),3.47–3.39(m,5H),3.30(m,2H),1.69(p,J=6.7Hz,2H),1.02(d,J=6.3Hz,3H).MS(ESI):m/z 461.2[M+H] + .
Example E27- (4-chlorobenzyl) -1- (3-hydroxypropyl) -3-methyl-8- (4-methylpent-1-yn-1-yl) -3, 7-dihydro-1H-purine-2, 6-dione
The synthesis of example E27 is identical to E24, except that starting from 4-methyl-1-pentyne instead of 3-butyn-2-ol. 1H-NMR (500MHz, DMSO-d 6) delta 7.47-7.39 (m, 2H), 7.30 (d, J =8.3Hz, 2H), 5.54 (s, 2H), 4.47 (t, J =5.2Hz, 1H), 3.95-3.88 (m, 2H), 3.47-3.39 (m, 5H), 2.48 (d, J =6.4Hz, 2H), 1.88 (hept, J =6.6Hz, 1H), 1.69 (p, J =6.5Hz, 2H), 0.95 (d, J =6.7Hz, 6H). MS (ESI): m/z.2 [ M ]. M + H ], (M + H)] + .
Example E28- (4-chlorobenzyl) -1- (3-hydroxypropyl) -3-methyl-8- (3- ((4-oxocyclohexyl) oxy) prop-1-yn-1-yl) -3, 7-dihydro-1H-purine-2, 6-dione
The synthesis of example E28 is as for E20, except that 4-hydroxycyclohexanone acetal is used instead of cyclohexanol as starting material. 1 H-NMR(500MHz,DMSO-d6)δ7.46–7.41(m,2H),7.36–7.30(m,2H),5.58(s,2H),4.63(s,2H),4.47(t,J=5.2Hz,1H),3.95–3.90(m,2H),3.87(tt,J=6.6,3.4Hz,1H),3.47–3.39(m,5H),2.35(ddd,J=14.7,8.9,5.9Hz,2H),2.24–2.15(m,2H),2.05–1.84(m,4H),1.69(p,J=6.6Hz,2H).MS(ESI):m/z 499.2[M+H] + .
Example E29- (4-chlorobenzyl) -1- (3-hydroxypropyl) -3-methyl-8- (3- (pyrrolidin-1-yl) but-1-yn-1-yl) -3, 7-dihydro-1H-purine-2, 6-dione
Intermediate INT 24-1 (300mg, 0.6 mmol) and triethylamine (0.34mL, 2.4 mmol) were dissolved in 20mL of ultra-dry dichloromethane and treated with N 2 Protecting, and cooling in ice bath. Methanesulfonyl chloride (89mg, 0.78mmol) was dissolved in 2mL of dichloromethane and added dropwise over 2min to the flask and stirred for about half an hour to complete the reaction as detected by TLC. Quenching with saturated aqueous ammonium chloride solution, separating dichloromethane phase, washing with brine for 2 times, anhydrous MgSO 4 Dried and then chromatographed on flash silica gel to give 312mg of gum, intermediate INT 29-1.
Intermediate INT 29-1 (312mg, 0.54mmol) was dissolved in 10mL acetonitrile and K was added 2 CO 3 (149mg, 1.08mmol) followed by the addition of pyrrolidine (58mg, 0.81mmol), N 2 The reaction was heated at 75 ℃ for 4 hours under protection and TLC indicated completion. The inorganic material was removed by filtration and the filtrate was chromatographed on flash silica gel to give 89mg of gum, intermediate INT 29-2.
Intermediate INT 29-2 (89mg, 0.162mmol) was dissolved in 2mL DCM, then 0.4mL TFA was added, stirred at room temperature for 1h, TLC indicated complete reaction. The solvent was evaporated under reduced pressure and the residue was purified by preparative liquid chromatography using acetonitrile/water system as mobile phase, the target product fraction was collected and evaporated to dryness to give 42mg of white solid as example E29. 1 H-NMR(500MHz,DMSO-d6)δ7.46–7.41(m,2H),7.28–7.22(m,2H),5.58(s,2H),4.45(t,J=5.2Hz,1H),4.00(d,J=6.8Hz,1H),3.95–3.88(m,2H),3.43(m,5H),2.48(m,4H),1.69(dq,J=9.0,6.6Hz,2H),1.61(s,4H),1.36(d,J=7.1Hz,3H).MS(ESI):m/z 470.2[M+H] + .
Example E30- (4-chlorobenzyl) -8- (3- ((4-hydroxycyclohexyl) oxy) prop-1-yn-1-yl) -1- (3-hydroxypropyl) -3-methyl-3, 7-dihydro-1H-purine-2, 6-dione
EXAMPLE Compound E28 (50mg, 0.1mmol) was dissolved in 2mL of methanol and NaBH was added 4 (7.6mg, 0.2mmol), stirred for 5min and TLC indicated completion of the reaction. Pouring into saturated NaCl aqueous solution, extracting with ethyl acetate for 3 times, combining organic phases, anhydrous MgSO 4 Drying, separating with flash silica gel chromatography column, eluting with dichloromethane/methanol system as mobile phase, collecting target product, and evaporating to dryness to obtain 38mg white solid, i.e. example E30. 1 H-NMR(500MHz,DMSO-d6)δ7.46–7.39(m,2H),7.33(dq,J=9.1,2.7Hz,2H),4.51(s,2H),4.47(t,J=5.2Hz,1H),3.95–3.89(m,2H),3.59–3.37(m,7H),1.90(dt,J=13.2,4.8Hz,1H),1.80–1.64(m,4H),1.55–1.39(m,4H),1.21–1.12(m,1H).MS(ESI):m/z 501.2[M+H] + .
Example E31- (4-chlorobenzyl) -8- (3, 3-dimethylbut-1-yn-1-yl) -1- (3-hydroxypropyl) -3-methyl-3, 7-dihydro-1H-purine-2, 6-dione
INT 2-2(100mg,0.196mmol)、PdCl 2 (Ph 3 P) 2 (20.6mg, 0.0294mmol), cuI (11.17mg, 0.0588mmol), 3mL of triethylamine, and 1mL of DMF were placed in a pressure-resistant tube, degassed with nitrogen for 3min, then 3, 3-dimethyl-1-butyne (82mg, 1mmol) was added, and further degassed for 1min. The pressure tube was sealed and heated at 60 ℃ for 6h. Cooling, diluting with ethyl acetate, filtering to remove insoluble substances, and filteringEvaporating to dryness under reduced pressure to obtain crude product. And then separating by using a flash silica gel chromatographic column, eluting by using MeOH/DCM as a mobile phase, collecting a target product part, and evaporating to dryness to obtain 91mg of a white solid, namely the intermediate INT 31-1.
Intermediate INT 31-1 (91mg, 0.178mmol) was dissolved in 2mL DCM, followed by the addition of 0.4mL TFA, stirring at RT for 1h, and TLC indicated completion of the reaction. The solvent was evaporated under reduced pressure and the residue was purified by preparative liquid chromatography using acetonitrile/water system as the mobile phase, the target product fraction was collected and evaporated to dryness to give 52mg of white solid, example E31. 1 H-NMR(500MHz,DMSO-d6)δ7.45(d,J=8.4Hz,2H),7.35(d,J=8.2Hz,2H),5.53(s,2H),4.48(t,J=5.2Hz,1H),3.93(t,J=7.5Hz,2H),3.44(q,J=6.0Hz,2H),3.40(s,3H),1.70(p,J=6.6Hz,2H),1.30(s,9H);MS(ESI):m/z 429.2[M+H] + .
Example E32- (4-chlorobenzyl) -8- (cyclopentylacetylene) -1- (3-hydroxypropyl) -3-methyl-3, 7-dihydro-1H-purine-2, 6-dione
The synthesis of example E32 is the same as E31 except that starting from cyclopentylacetylene instead of 3, 3-dimethyl-1-butyne. 1 H NMR(500MHz,DMSO-d6)δ7.44(d,J=8.0Hz,2H),7.32(d,J=8.5Hz,2H),5.52(s,2H),4.48(t,J=5.2Hz,1H),3.92(t,J=7.5Hz,2H),3.44(q,J=6.1Hz,2H),3.40(s,3H),3.01(p,J=7.4Hz,1H),1.99(m,2H),1.73–1.54(m,8H);MS(ESI):m/z 441.2[M+H] + .
Example E33- (4-chlorobenzyl) -8- (cyclohexylacetylene) -1- (3-hydroxypropyl) -3-methyl-3, 7-dihydro-1H-purine-2, 6-dione
The synthesis of example E33 is identical to E31, except that cyclohexylacetylene is used instead of 3, 3-dimethyl-1-butyne as starting material. 1 H-NMR(500MHz,DMSO-d6)δ7.44(d,J=8.4Hz,2H),7.32(d,J=8.5Hz,2H),5.53(s,2H),4.48(t,J=5.2Hz,1H),3.92(t,J=7.5Hz,2H),3.45(m,2H),3.40(s,3H),2.80(m,1H),1.81(m,2H),1.69(m,2H),1.59(m,2H),1.49(m,3H),1.34(m,3H);MS(ESI):m/z 455.2[M+H] + .
Example E34- (4-chlorobenzyl) -8- (3-cyclohexylpropyl-1-yn-1-yl) -1- (3-hydroxypropyl) -3-methyl-3, 7-dihydro-1H-purine-2, 6-dione
The synthesis of example E34 is as for E31, except that 3-cyclohexylpropyne is used instead of 3, 3-dimethyl-1-butyne as starting material. 1 H-NMR(500MHz,DMSO-d6)δ7.45–7.40(m,2H),7.27(d,J=8.2Hz,2H),5.54(s,2H),4.47(t,J=5.2Hz,1H),3.95–3.88(m,2H),3.44(q,J=6.2Hz,2H),3.41(s,3H),2.46(d,J=6.5Hz,2H),1.73–1.55(m,7H),1.49(m,1H),1.18(m2H),1.06(m,1H),1.00–0.89(m,2H);MS(ESI):m/z 469.2[M+H] + .
Example E35- ((1R, 3S,5r, 7r) -adamantan-2-yl) ethynyl) -7- (4-chlorobenzyl) -1- (3-hydroxypropyl) -3-methyl-3, 7-dihydro-1H-purine-2, 6-dione
The synthesis of example E35 is as for E31, except that 1-ethynyladamantane is used as starting material instead of 3, 3-dimethyl-1-butyne. 1 H-NMR(500MHz,Chloroform-d)δ7.46–7.40(m,2H),7.34(d,J=6.6Hz,1H),4.19(t,J=6.0Hz,2H),3.58(s,3H),3.53(m,2H),3.41(m,1H),2.06(m,3H),2.03(m,6H),1.91(p,J=5.7Hz,2H),1.81–1.73(m,6H);MS(ESI):m/z 507.2[M+H] + .
Example E36- (4-chlorobenzyl) -1- (3-hydroxypropyl) -3-methyl-8- (3- (4-methylpiperidin-1-yl) but-1-yn-1-yl) -3, 7-dihydro-1H-purine-2, 6-dione
Example E36 SynthesisThe preparation method is the same as E29 except that 4-methylpiperidine is used as a raw material instead of pyrrolidine. 1 H-NMR(500MHz,Chloroform-d)δ7.33(s,4H),5.59(s,2H),4.19(t,J=6.0Hz,2H),3.83(q,J=7.1Hz,1H),3.60(s,3H),3.53(t,J=5.5Hz,2H),2.93(d,J=10.9Hz,1H),2.78(d,J=11.0Hz,1H),2.38(d,J=2.8Hz,1H),2.09(d,J=2.6Hz,1H),1.91(p,J=5.7Hz,2H),1.67(m,6H),1.50(d,J=7.1Hz,3H),0.94(d,J=5.4Hz,3H);MS(ESI):m/z 498.2[M+H] + .
Example E37- (4-chlorobenzyl) -8- (3-ethoxybut-1-yn-1-yl) -1- (3-hydroxypropyl) -3-methyl-3, 7-dihydro-1H-purine-2, 6-dione
Potassium hydroxide (364mg, 6.5 mmol) was placed in 8mL DMSO, 3-butyn-2-ol (0.37mL, 5 mmol) was added, and stirring was carried out at room temperature for 20min, followed by iodoethane (440. Mu.L, 5.5 mmol), and stirring was carried out overnight at room temperature. Ice water was added to the flask and neutralized with acetic acid. Then extracted with 8mL of methyl tert-butyl ether, washed twice with brine and dried over anhydrous magnesium sulfate. Magnesium sulfate was removed by filtration, and the filtrate was made to volume of 10mL to obtain a methyl tert-butyl ether solution of intermediate INT 37-1 at a concentration of 0.5 mol/L.
INT 2-2(100mg,0.196mmol)、PdCl 2 (Ph 3 P) 2 (20.6mg, 0.0294mmol), cuI (11.17mg, 0.0588mmol), 3mL of triethylamine, and 1mL of DMF were placed in a pressure-resistant tube, degassed with nitrogen for 3min, then intermediate INT 37-1 (1.6mL, 0.8mmol) was added, and further degassed for 1min. The pressure tube was sealed and heated at 60 ℃ for 4h. After cooling, the mixture was diluted with ethyl acetate, the insoluble matter was removed by filtration, and the filtrate was evaporated to dryness under reduced pressure to give a crude product. Separation was then carried out by preparative plate TLC, meOH/DCM was developed and the desired product fractions were collected as 30mg of gum, intermediate INT 37-2.
Intermediate INT 37-2 (30mg, 0.057mmol) was dissolved in 2mL DCM and 0.4mL TFA was added and stirred at RT for 1h, TLC indicated completion of the reaction. Evaporating under reduced pressure to remove solvent, purifying the residue with preparative liquid chromatography column, eluting with acetonitrile/water system as mobile phase, collecting target product,evaporation to dryness afforded 12mg of a white solid, example E37. 1 H-NMR(500MHz,CD 3 OD)δ7.38(s,4H),5.65(m,2H),4.52(q,J=6.5Hz,1H),4.11(t,J=7.0Hz,2H),3.73(m,1H),3.62(t,J=6.5Hz,2H),3.54(s,3H),3.51(m,1H),1.87(m,2H),1.53(d,J=7.0Hz,3H),1.21(t,J=7.0Hz,3H);MS(ESI):m/z 445.2[M+H] + .
Example E38- (4-chlorobenzyl) -8- (3- (cyclopropylmethoxy) but-1-yn-1-yl) -1- (3-hydroxypropyl) -3-methyl-3, 7-dihydro-1H-purine-2, 6-dione
The synthesis of example E38 is as for E37, except that bromomethylcyclopropane is used instead of iodoethane as starting material. 1 H-NMR(500MHz,Chloroform-d)δ7.38(d,J=8.5Hz,2H),7.33(d,J=8.5Hz,2H),5.57(m,2H),4.52(q,J=6.5Hz,1H),4.20(t,J=6.0Hz,2H),3.59(s,3H),3.54(m,3H),3.33(m,2H),1.91(m,2H),1.61(d,J=7.0Hz,3H),1.06(m,1H),0.59(m,2H),0.23(m,2H);MS(ESI):m/z 471.2[M+H] + .
Example E39- (4-chlorobenzyl) -1- (3-hydroxypropyl) -3-methyl-8- (3-methyl-3- (4-methylpiperidin-1-yl) but-1-yn-1-yl) -3, 7-dihydro-1H-purine-2, 6-dione
3-chloro-3-methyl-1-butyne (1.02g, 10mmol), 4-methylpiperidine (0.991g, 10mmol) were dissolved in 10mL of ultra-dry tetrahydrofuran, triethylamine (1.67mL, 12mmol) was added, and the mixture was stirred with N 2 Protecting, cooling to 0 deg.C in ice bath, suspending CuI (0.38g, 2mmol) in 5mL tetrahydrofuran, adding dropwise into the reaction system with constant pressure dropping funnel, reacting overnight at room temperature, detecting with thin layer chromatography, developing with potassium permanganate developer, pouring saturated NaCl aqueous solution, extracting with ethyl acetate for 2 times, anhydrous MgSO, and allowing to stand for a while 4 Drying, filtering and evaporating to dryness, and then making the volume to 10mL to obtain a tetrahydrofuran solution of which the concentration of the intermediate INT 39-1 is 1 mol/L.
INT 2-2(100mg,0.196mmol)、PdCl 2 (Ph 3 P) 2 (20.6mg, 0.0294mmol), cuI (11.17mg, 0.0588mmol), 3mL of triethylamine, and 1mL of DMF were placed in a pressure-resistant tube, degassed with nitrogen for 3min, then intermediate INT 39-1 (1mL, 1mmol) was added, and further degassed for 1min. The pressure tube was sealed and heated at 60 ℃ for 4h. After cooling, diluting with ethyl acetate, filtering to remove insoluble substances, and evaporating the filtrate under reduced pressure to obtain a crude product. Separating with flash silica gel chromatography column, eluting with MeOH/DCM as mobile phase, collecting target product, and evaporating to dryness to obtain 91mg of jelly, namely intermediate INT 39-2.
Intermediate INT 39-2 (91mg, 0.153mmol) was dissolved in 2mL DCM, then 0.4mL TFA was added, stirred at RT for 1h, TLC indicated complete reaction. The solvent was evaporated under reduced pressure and the residue was purified by preparative liquid chromatography using acetonitrile/water system as the mobile phase, the target product fraction was collected and evaporated to dryness to give 46mg of a white solid, example E39. 1 H-NMR(500MHz,Chloroform-d)δ7.33(s,4H),5.59(s,2H),3.61(s,3H),3.53(q,J=5.5Hz,3H),3.10(d,J=10.8Hz,2H),2.16–2.08(m,2H),2.04(m,1H),1.91(p,J=5.7Hz,2H),1.68(m,4H),1.54(s,6H),1.36–1.32(m,2H),0.94(d,J=5.8Hz,3H).MS(ESI):m/z 512.2[M+H] + .
Example E40- (4-chlorobenzyl) -8- (cyclopropylethynyl) -1- (3-hydroxypropyl) -3-methyl-3, 7-dihydro-1H-purine-2, 6-dione
The synthesis of example E40 is as for E31, except that cyclopropylacetylene is used instead of 3, 3-dimethyl-1-butyne as starting material. 1 H-NMR(500MHz,DMSO-d6)δ7.45(m,2H d,J=8.5Hz,2H),7.32(d,J=8.5Hz,2H),5.51(s,2H),4.46(t,J=5.3Hz,1H),3.92(t,J=7.5Hz,2H),3.44(m,2H),3.39(s,3H),1.74–1.65(m,3H),1.01(m,2H),0.89–0.82(m,2H);MS(ESI):m/z 413.1[M+H] + .
Example E41- (4-chlorobenzyl) -8- (3- (cyclopentylamino) -3-methylbut-1-yn-1-yl) -1- (3-hydroxypropyl) -3-methyl-3, 7-dihydro-1H-purine-2, 6-dione
The synthesis of example E41 is as for E39, except that cyclopentylamine is used as starting material instead of 4-methylpiperidine. 1 H-NMR(500MHz,DMSO-d6)δ7.46–7.41(m,2H),7.29(d,J=8.4Hz,2H),5.55(s,2H),4.46(t,J=5.2Hz,1H),3.91(dd,J=8.3,6.5Hz,2H),3.43(d,J=12.8Hz,5H),3.18(d,J=5.2Hz,1H),3.06(p,J=7.2Hz,1H),1.73–1.65(m,4H),1.57–1.48(m,2H),1.36(s,6H),1.21(m,2H);MS(ESI):m/z 498.2[M+H] + .
Example E42- (4-chlorobenzyl) -8- (3- ((3, 3-difluorocyclobutyl) amino) -3-methylbut-1-yn-1-yl) -1- (3-hydroxypropyl) -3-methyl-3, 7-dihydro-1H-purine-2, 6-dione
The synthesis of example E42 is as for E39, except that 3, 3-difluorocyclobutylamine is used as starting material instead of 4-methylpiperidine. 1 H-NMR(500MHz,DMSO-d6)δ7.47–7.41(m,2H),7.31(d,J=8.4Hz,2H),5.55(s,2H),4.47(t,J=5.2Hz,1H),4.12(q,J=5.3Hz,1H),3.96–3.89(m,2H),3.44(q,J=6.1Hz,2H),3.41(s,3H),3.18(d,J=4.6Hz,2H),2.71(m,2H),2.37(m,2H),1.69(p,J=6.6Hz,2H),1.35(s,6H).MS(ESI):m/z 520.2[M+H] + .
Example E43- (4-chlorobenzyl) -8- (3- (cyclopropyl (methyl) amino) -3-methylbut-1-yn-1-yl) -1- (3-hydroxypropyl) -3-methyl-3, 7-dihydro-1H-purine-2, 6-dione
The synthesis of example E43 is as for E39, except that N-methylcyclopropane is used instead of 4-methylpiperidine as starting material. 1 H-NMR(500MHz,DMSO-d6)δ7.47–7.40(m,2H),7.30–7.24(m,2H),5.59(s,2H),4.48(t,J=5.2Hz,1H),3.97–3.88(m,2H),3.44(d,J=9.5Hz,5H),2.25(s,3H),1.74–1.66(m,2H),1.61(tt,J=6.8,3.8Hz,1H),1.43(s,6H),0.52–0.45(m,2H),0.38–0.31(m,2H).MS(ESI):m/z 484.2[M+H] + .
Example E44- (4-chlorobenzyl) -8- (3- (cyclobutylmethoxy) but-1-yn-1-yl) -1- (3-hydroxypropyl) -3-methyl-3, 7-dihydro-1H-purine-2, 6-dione
The synthesis of example E44 is the same as E37 except bromomethylcyclobutane is used instead of iodoethane. 1 H-NMR(500MHz,Chloroform-d)δ7.39(d,J=8.5Hz,2H),7.33(d,J=8.5Hz,2H),5.58(m,2H),4.45(q,J=7.0Hz,1H),4.20(t,J=6.0Hz,2H),3.69(dd,J=7.0,2.0Hz,1H),3.60(s,3H),3.55(t,J=6.0Hz,2H),3.45(dd,J=7.0,2.0Hz,1H),3.32(brs,1H,-OH),2.60(m,1H),2.08(m,2H),1.92(m,4H),1.74(m,2H),1.59(d,J=6.5Hz,3H);MS(ESI):m/z 485.2[M+H] + .
EXAMPLE E45- (4-chlorobenzyl) -8- (3- (cyclopropylmethoxy) -3-methylbut-1-yn-1-yl) -1- (3-hydroxypropyl) -3-methyl-3, 7-dihydro-1H-purine-2, 6-dione
The synthesis of example E45 is carried out as in E37, except that bromomethylcyclopropane is used instead of iodoethane and 2-methyl-3-butyn-2-ol is used instead of 3-butyn-2-ol as starting material. 1 H-NMR(500MHz,Chloroform-d)δ7.37(d,J=8.5Hz,2H),7.34(d,J=8.5Hz,2H),5.58(s,2H),4.20(t,J=6.0Hz,2H),3.60(s,3H),3.54(m,2H),3.41(d,J=7.0Hz,2H),3.31(t,1H,-OH),1.91(m,2H),1.62(s,6H),1.08(m,1H),0.57(m,2H),0.21(m,2H);MS(ESI):m/z 485.2[M+H] + .
Example E46- (4-chlorobenzyl) -8- (3- (cyclopentyloxy) but-1-yn-1-yl) -1- (3-hydroxypropyl) -3-methyl-3, 7-dihydro-1H-purine-2, 6-dione
The synthesis of example E46 is as for E37 except that bromocyclopentane is used as the starting material instead of iodoethane. 1 H-NMR(500MHz,Chloroform-d)δ7.41(d,J=8.5Hz,2H),7.33(d,J=8.5Hz,2H),5.58(m,2H),4.48(q,J=6.5Hz,1H),4.20(m,3H),3.60(s,3H),3.55(t,J=5.5Hz,2H),2.04(m,1H),1.92(m,2H),1.81(m,1H),1.74(m,4H),1.67(m,1H),1.57(d,J=6.5Hz,3H),1.54(m,1H);MS(ESI):m/z 485.2[M+H] + .
Example E47:7- (4-chlorobenzyl) -8- (4-fluorophenyl) ethynyl) -1- (3-hydroxypropyl) -3-methyl-3, 7-dihydro-1H-purine-2, 6-dione
The synthesis of example E47 is as for E31, except that 1-ethynyl-4-fluorobenzene is used as starting material instead of 3, 3-dimethyl-1-butyne. 1 H-NMR(500MHz,Chloroform-d)δ7.63(dd,J=8.5,5.5Hz,2H),7.44(d,J=8.5Hz,2H),7.35(d,J=8.5Hz,2H),7.16(t,J=9.0Hz,2H),5.64(s,2H),4.22(t,J=6.0Hz,2H),3.63(s,3H),3.56(m,2H),3.33(brs,1H,-OH),1.93(m,2H);MS(ESI):m/z 467.1[M+H] + .
Example E48:7- (4-chlorobenzyl) -1- (3-hydroxypropyl) -3-methyl-8- (pyridin-2-ylethynyl) -3, 7-dihydro-1H-purine-2, 6-dione
The synthesis of example E48 is as for E31, except that 2-ethynylpyridine is used as starting material instead of 3, 3-dimethyl-1-butyne. 1 H-NMR(500MHz,Chloroform-d)δ8.74(d,J=6.0Hz,1H),7.81(t,J=7.5Hz,1H),7.68(d,J=7.0Hz,1H),7.55(d,J=8.5Hz,2H),7.42(m,1H),7.33(d,J=8.5Hz,2H),5.70(s,2H),4.23(t,J=6.0Hz,2H),3.63(s,3H),3.56(m,2H),3.32(brs,1H,-OH),1.94(m,2H);MS(ESI):m/z 450.1[M+H] + .
Example E49:7- (4-chlorobenzyl) -1- (3-hydroxypropyl) -3-methyl-8- (thien-2-ylethynyl) -3, 7-dihydro-1H-purine-2, 6-dione
The synthesis of example E49 is as for E31, except that 2-ethynylthiophene is used as starting material instead of 3, 3-dimethyl-1-butyne. 1 H-NMR(500MHz,Chloroform-d)δ7.52(d,J=5.0Hz,1H),7.50(d,J=3.5Hz,1H),7.45(d,J=8.5Hz,2H),7.35(d,J=8.0Hz,2H),7.14(t,J=4.5Hz,1H),5.63(s,2H),4.22(t,J=6.0Hz,2H),3.62(s,3H),3.57(m,2H),3.37(brs,1H,-OH),1.94(m,2H);MS(ESI):m/z 455.1[M+H] + .
Example E50:7- (4-chlorobenzyl) -1- (3-hydroxypropyl) -3-methyl-8- (3-oxobut-1-yn-1-yl) -3, 7-dihydro-1H-purine-2, 6-dione
INT 2-2(255mg,0.5mmol)、PdCl 2 (Ph 3 P) 2 (52.5mg, 0.074mmol), cuI (28.5mg, 0.15mmol), 3mL of triethylamine and 1mL of DMF were placed in a pressure-resistant tube, degassed with nitrogen for 3min, followed by addition of 3-butyn-2-ol (175mg, 2.5mmol) and further degassing for 1min. The pressure tube was sealed and heated at 60 ℃ for 4h. After cooling, diluting with ethyl acetate, filtering to remove insoluble substances, and evaporating the filtrate under reduced pressure to obtain a crude product. Separating with flash silica gel chromatography column, eluting with MeOH/DCM as mobile phase, collecting target product, and evaporating to dryness to obtain 91mg of jelly, namely intermediate INT 50-1.
Intermediate INT 50-1 (100mg, 0.2mmol) was dissolved in 2mL DCM, dess-Martin oxidant (170mg, 0.4mmol) was added, stirring was carried out at RT for 3h, TLC indicated completion of the reaction. DCM/saturated NaHCO 3 And (3) distributing the aqueous solution, separating an organic phase, drying by using anhydrous sodium sulfate, separating by using a flash silica gel chromatographic column, eluting by using MeOH/DCM as a mobile phase, collecting a target product part, and evaporating to dryness to obtain 73mg of jelly, namely an intermediate INT 50-2.
Intermediate INT 50-2 (73mg, 0.151mmol) was dissolved in 2mL DCM, then 0.4mL TFA was added,the reaction was stirred at room temperature for 1h and TLC showed completion. The solvent was evaporated under reduced pressure and the residue was purified by preparative liquid chromatography using acetonitrile/water system as mobile phase, the target product fraction was collected and evaporated to dryness to obtain 32mg of white solid, example E50. 1 H-NMR(500MHz,Chloroform-d)δ7.45–7.39(m,2H),7.37–7.31(m,2H),5.62(s,2H),4.22(t,J=6.1Hz,2H),3.60(s,3H),3.56(t,J=5.6Hz,2H),2.54(s,3H),1.93(p,J=5.8Hz,2H);MS(ESI):m/z 415.1[M+H] + .
Example E51: (E) -7- (4-chlorobenzyl) -8- (2-cyclopropylvinyl) -1- (3-hydroxypropyl) -3-methyl-3, 7-dihydro-1H-purine-2, 6-dione
INT 2-2 (100mg, 0.196mmol), (E) -2-cyclopropylvinylboronic acid pinacol ester (95mg, 0.49mmol), pd (dppf) Cl 2 (21.5mg,0.029mmol)、Cs 2 CO 3 (191mg, 0.588 mmol), 1, 4-dioxane 10mL, and H 2 O3 mL was placed in a pressure tube, degassed with nitrogen for 3min, sealed, and heated at 100 ℃ for 2h. After cooling, diluting with ethyl acetate, filtering to remove insoluble substances, and evaporating the filtrate under reduced pressure to obtain a crude product. And separating by using a flash silica gel chromatographic column, eluting by using MeOH/DCM as a mobile phase, collecting a target product part, and evaporating to dryness to obtain 85mg of jelly, namely an intermediate INT 51-1.
Intermediate INT 51-1 (85mg, 0.176mmol) was dissolved in 2mL DCM, then 0.4mL TFA was added, stirred at RT for 1h, TLC indicated complete reaction. The solvent was evaporated under reduced pressure and the residue was purified by preparative liquid chromatography using acetonitrile/water system as the mobile phase, the target product fraction was collected and evaporated to dryness to afford 40mg of a white solid, example E51. 1 H-NMR(500MHz,Chloroform-d)δ7.38–7.32(m,2H),7.22–7.13(m,2H),6.56(dd,J=15.1,10.0Hz,1H),6.37(d,J=15.1Hz,1H),5.56(s,2H),4.23–4.13(m,2H),3.61(s,3H),3.56–3.49(m,2H),1.91(p,J=5.8Hz,2H),1.68–1.62(m,1H),1.07–0.95(m,2H),0.76–0.71(m,2H);MS(ESI):m/z 413.1[M+H] + .
Example E52- (4-chlorophenyl) -1- (3-hydroxypropyl) -3-methyl-8- (3-methyl-3- (methylsulfonyl) but-1-yn-1-yl) -3, 7-dihydro-1 h-purine-2, 6-dione
Sodium methanesulfonate (830mg, 7.033mmol) and CuCl (77mg, 0.778mmol) were dissolved in 10mL of DMF, and 3-chloro-3-methyl-1-butyne (1g, 9.8mmol) was slowly added dropwise thereto, and the mixture was heated at 40 ℃ for 12 hours. TLC showed the reaction was complete. And (3) filtering, concentrating the filtrate, separating by using a flash silica gel chromatographic column, eluting by using MeOH/DCM as a mobile phase, collecting a target product part, and evaporating to dryness to obtain 184mg of jelly, namely an intermediate INT 52-1.
INT 2-2(100mg,0.196mmol)、PdCl 2 (Ph 3 P) 2 (20.6mg, 0.0294mmol), cuI (11.17mg, 0.0588mmol), 3mL of triethylamine, and 1mL of DMF were placed in a pressure-resistant tube, degassed with nitrogen for 3min, then intermediate INT 52-1 (85mg, 0.582mmol) was added, and degassed for 1min. The pressure tube was sealed and heated at 60 ℃ for 4h. After cooling, diluting with ethyl acetate, filtering off insoluble substances, and evaporating the filtrate under reduced pressure to obtain a crude product. Separating with flash silica gel chromatography column, eluting with MeOH/DCM as mobile phase, collecting target product, and evaporating to dryness to obtain 50mg of jelly, namely intermediate INT 52-2.
Intermediate INT 52-2 (50mg, 0.089mmol) was dissolved in 2mL DCM, then 0.4mL TFA was added, stirred at RT for 1h, TLC indicated complete reaction. The solvent was evaporated under reduced pressure and the residue was purified by preparative liquid chromatography using acetonitrile/water system as the mobile phase, the target product fraction was collected and evaporated to dryness to obtain 25mg of white solid, example E52. 1 H-NMR(500MHz,Chloroform-d)δ7.44–7.37(m,2H),7.37–7.32(m,2H),5.60(s,2H),4.22(t,J=6.1Hz,2H),3.60(s,3H),3.58–3.53(m,2H),3.00(s,3H),1.93(m,2H),1.82(s,6H);MS(ESI):m/z 493.1[M+H] + .
Example E53 (E) -7- (4-chlorobenzyl) -1- (3-hydroxypropyl) -3-methyl-8- (pent-1-en-1-yl) -3, 7-dihydro-1H-purine-2, 6-dione
INT 2-2 (100mg, 0.196mmol), trans-1-penten-1-ylboronic acid pinacol ester (96.1mg, 0.49mmol), pd (dppf) Cl 2 (21.5mg,0.029mmol)、Cs 2 CO 3 (191mg, 0.588 mmol), 1, 4-dioxane 10mL, and H 2 O3 mL was placed in a pressure tube, degassed with nitrogen for 3min, sealed, and heated at 100 ℃ for 2h. After cooling, diluting with ethyl acetate, filtering to remove insoluble substances, and evaporating the filtrate under reduced pressure to obtain a crude product. Separating with flash silica gel chromatography column, eluting with MeOH/DCM as mobile phase, collecting target product, and evaporating to dryness to obtain 100mg of jelly, i.e. intermediate INT 51-1.
Intermediate INT 51-1 (100mg, 0.2mmol) was dissolved in 2mL DCM, then 0.4mL TFA was added, stirred at room temperature for 1h, and TLC indicated complete reaction. The solvent was evaporated under reduced pressure and the residue was purified by preparative liquid chromatography using acetonitrile/water system as the mobile phase, the target product fraction was collected and evaporated to dryness to give 50mg of a white solid, example E51. 1 H-NMR(500MHz,Chloroform-d)δ7.37–7.31(m,2H),7.20–7.14(m,2H),7.10(dt,J=15.4,7.1Hz,1H),6.31(dt,J=15.4,1.6Hz,1H),5.57(s,2H),4.26–4.09(m,2H),3.63(s,3H),3.57–3.49(m,2H),2.30(qd,J=7.2,1.6Hz,2H),1.91(p,J=5.8Hz,2H),1.56(p,J=7.4Hz,2H),0.98(t,J=7.3Hz,3H);MS(ESI):m/z 417.2[M+H] + .
EXAMPLE E54 Ethyl propionate 3- (7- (4-chlorobenzyl) -1- (3-hydroxypropyl) -3-methyl-2, 6-dioxo-2, 3,6, 7-tetrahydro-1H-purin-8-yl)
Trimethylsilyne (980mg, 10mmol) was dissolved in 20mL of diethyl ether, isopropylmagnesium bromide (1.617g, 11mmol) was added thereto, the mixture was stirred at room temperature for 1 hour, heated at 150 ℃ and refluxed for 15 minutes, cooled to room temperature, tetraethyl orthocarbonate (2.208g, 11.5 mmol) was added thereto, and the mixture was stirred at 45 ℃ for 12 hours. TLC showed the reaction was complete. And (3) distributing EA/saturated NaCl aqueous solution, separating an organic phase, drying by anhydrous sodium sulfate, separating by using a flash silica gel chromatographic column, eluting by using PE/EA as a mobile phase, collecting a target product part, and evaporating to dryness to obtain 1.05g of liquid, namely an intermediate INT 54-1.
INT 54-1 (1g, 4.098mmol) was dissolved in 5mL of THF, TBAF (5.3mL, 6.147mmol) was added, and the mixture was stirred at room temperature for 15min. TLC shows that the reaction is finished, the solvent is removed by reduced pressure distillation, the separation is carried out by a flash silica gel chromatographic column, PE/EA is used as a mobile phase for elution, the target product part is collected, and 700mg of liquid, namely the intermediate INT 54-2, is obtained by evaporation.
INT 2-2(100mg,0.196mmol)、PdCl 2 (Ph 3 P) 2 (20.6 mg, 0.0294mmol), cuI (11.17mg, 0.0588mmol), triethylamine 3mL, and 1mL of DMF were placed in a pressure tube, degassed with nitrogen for 3min, then intermediate INT 54-2 (100mg, 0.582mmol) was added, and degassed for 1min. The pressure tube was sealed and heated at 60 ℃ for 4h. After cooling, the mixture was diluted with ethyl acetate, insoluble matter was filtered off, and the filtrate was evaporated to dryness under reduced pressure to give a crude product. Separating with flash silica gel chromatography column, eluting with MeOH/DCM as mobile phase, collecting target product, and evaporating to dryness to obtain 80mg of jelly, namely intermediate INT 54-3.
Intermediate INT 52-2 (80mg, 0.133mmol) was dissolved in 2mL DCM, then 0.4mL TFA was added, stirred at room temperature for 1h, TLC indicated complete reaction. The solvent was evaporated under reduced pressure and the residue was purified by preparative liquid chromatography using acetonitrile/water system as the mobile phase, the target product fraction was collected and evaporated to dryness to obtain 45mg of white solid, example E54. 1 H-NMR(500MHz,Chloroform-d)δ7.48–7.43(m,2H),7.38–7.32(m,2H),5.63(s,2H),4.40(q,J=7.1Hz,2H),4.22(t,J=6.1Hz,2H),3.60(s,3H),3.58–3.54(m,2H),1.93(p,J=5.8Hz,2H),1.42(t,J=7.1Hz,3H);MS(ESI):m/z 445.1[M+H] + .
Example E55- (4-chlorobenzyl) -6- (cyclopentylethynyl) -3- (3-hydroxypropyl) -1-methyl-1, 5-dihydro-2H-pyrrolo [3,2-d ] pyrimidine-2, 4 (3H) -dione
6-Chlorouracil (10g, 68.493mmol)Dissolved in 40mL DMSO, K was added sequentially 2 CO 3 (4.8g,34.783mmol)、CH 3 I (12.7mL, 205.48mmol) was stirred at room temperature for 3h. TLC showed the reaction was complete, 50mL H was added 2 And O, performing suction filtration, and washing a filter cake to obtain 7.9g of white solid, namely the intermediate INT 55-1.
Intermediate INT 55-1 (1g, 6.25mmol) was dissolved in 10mL DMF and K was added 2 CO 3 (1.73g, 12.5 mmol) and 3-bromopropyl methyl ether (1.07mL, 9.375 mmol), and heated at 60 ℃ for 3 hours. TLC shows that the reaction is finished, EA/saturated NaCl aqueous solution is distributed, an organic phase is separated, anhydrous sodium sulfate is dried and then is separated by a flash silica gel chromatographic column, DCM/MeOH is used as a mobile phase for elution, a target product part is collected and is evaporated to dryness to obtain 800mg of jelly, namely an intermediate INT 55-2.
Intermediate INT 55-2 (1g, 4.31mmol) was dissolved in 3mL of concentrated sulfuric acid, stirred at 0 ℃ for 5min, 3mL of concentrated nitric acid was slowly added dropwise, and stirred at 0 ℃ for 1h. TLC shows that the reaction was complete, EA/ice water was partitioned, the organic layer was washed with saturated brine four times, dried over anhydrous sodium sulfate and separated by flash column chromatography on silica gel, eluted with DCM/MeOH as mobile phase, the target product fractions were collected and evaporated to dryness to obtain 800mg of gum, intermediate INT55-3.
Diethyl malonate (3.24mL, 21.66mmol) was dissolved in 10mL of dried 1, 4-dioxane, potassium tert-butoxide (2.1lg, 19.494mmol) was added and stirred at room temperature for 10min, then intermediate INT55-3 (3g, 10.83mmol) was added and stirred at room temperature for 1h. TLC shows that the reaction is finished, 2M HCl is adjusted to be acidic, EA/saturated NaCl aqueous solution is distributed, an organic phase is separated, anhydrous sodium sulfate is dried and then separated by a flash silica gel chromatographic column, DCM/MeOH is used as a mobile phase for elution, a target product part is collected, and 3.2g of jelly, namely the intermediate INT 55-4, is obtained by evaporation.
The intermediate INT 55-4 (3 g, 7.463mmol) is dissolved in 15mL of acetic acid, heated to 60 ℃, added with zinc powder (7.3g, 111.94mmol) and reacted for 12h in a pressure resistant tube at 120 ℃. TLC shows that the reaction is finished, and the crude product is obtained by reduced pressure evaporation. Then separating with flash silica gel chromatographic column, eluting with MeOH/DCM as mobile phase, collecting target product, and evaporating to dryness to obtain 1.8g of jelly, namely intermediate INT 55-5.
Intermediate INT55-5 (100mg, 7.463mmol) was dissolved in 3mL of dry 1, 4-dioxane, tribromooxyphosphorus (340mg, 22.389mmol) was added under nitrogen, and stirring was carried out at 100 ℃ for 1h. TLC showed completion of the reaction, EA/saturated NaHCO 3 Distributing the aqueous solution, separating an organic phase, drying by anhydrous sodium sulfate, separating by using a flash silica gel chromatographic column, eluting by using DCM/MeOH as a mobile phase, collecting a target product part, and evaporating to dryness to obtain 90mg of jelly, namely an intermediate INT 55-6.
Intermediate INT 55-6 (90mg, 0.286mmol) was dissolved in 5mL DMF and K was added 2 CO 3 (1.73g, 12.5 mmol) and 4-chlorobenzyl bromide (116mg, 0.572mmol), and heating at 60 ℃ for 2 hours. TLC shows that the reaction is finished, EA/saturated NaCl aqueous solution is distributed, an organic phase is separated, anhydrous sodium sulfate is dried and then is separated by a flash silica gel chromatographic column, DCM/MeOH is used as a mobile phase for elution, a target product part is collected and is evaporated to dryness to obtain 80mg of white solid, namely an intermediate INT 55-7.
Intermediate INT 55-7 (40mg, 0.091mmol) was dissolved in 3mL dry DCM and 182. Mu.L BBr 1M was added at 0 deg.C 3 The solution was stirred at this temperature for 1h. TLC shows that the reaction is finished, and the crude product is obtained by reduced pressure evaporation. Separating with flash silica gel chromatography column, eluting with MeOH/DCM as mobile phase, collecting target product, and evaporating to dryness to obtain 30mg white solid, namely intermediate INT 55-8.
INT 55-8(50mg,0.118mmol)、PdCl 2 (Ph 3 P) 2 (12mg, 0.0177mmol), cuI (7mg, 0.0354mmol), triethylamine 3mL and DMF 1mL were placed in a pressure tube, degassed with nitrogen for 3min, then cyclopentylacetylene (56mg, 0.588mmol) was added and degassed for 1min. The pressure tube was sealed and heated at 60 ℃ for 4h. After cooling, diluting with ethyl acetate, filtering to remove insoluble substances, and evaporating the filtrate under reduced pressure to obtain a crude product. Then separating with flash silica gel chromatography column, eluting with MeOH/DCM as mobile phase, collecting the target product, and evaporating to dryness to obtain 40mg of gum. The crude product was purified by preparative liquid chromatography, eluted with acetonitrile/water system as mobile phase, the target product fraction was collected and evaporated to dryness to obtain 25mg of white solid, example E55. 1 H-NMR(500MHz,Chloroform-d)δ7.30(s,4H),6.11(s,1H),5.61(s,2H),4.26–4.07(m,2H),3.51(t,J=5.5Hz,2H),3.45(s,3H),2.91(p,J=7.4Hz,1H),2.05(d,J=10.7Hz,3H),1.90(p,J=5.7Hz,2H),1.84–1.54(m,3H);MS(ESI):m/z 440.2[M+H] + .
Example E56 (E) -5- (4-chlorobenzyl) -6- (4-chlorophenylvinyl) -3- (3-hydroxypropyl) -1-methyl-1, 5-dihydro-2H-pyrrolo [3,2-d ] pyrimidine-2, 4 (3H) -dione
INT 55-8 (25mg, 0.049 mmol), (E) - (4-chlorostyryl) boronic acid (22.3mg, 0.122mmol), pd (dppf) Cl 2 (5.38mg,0.007mmol)、Cs 2 CO 3 (48mg, 0.147mmol), 1, 4-dioxane 10mL, and H 2 O3 mL was placed in a pressure tube, degassed with nitrogen for 3min, sealed, and heated at 100 ℃ for 2h. After cooling, diluting with ethyl acetate, filtering to remove insoluble substances, and evaporating the filtrate under reduced pressure to obtain a crude product. Then separating with flash silica gel chromatography column, eluting with MeOH/DCM as mobile phase, collecting the target product, and evaporating to dryness to obtain 25mg of gum. The crude product was purified by preparative liquid chromatography, eluted with acetonitrile/water system as mobile phase, the target product fraction was collected and evaporated to dryness to give 15mg of a white solid, example E56. 1 H-NMR(500MHz,Chloroform-d)δ7.37(s,4H),7.34–7.30(m,2H),7.16–7.03(m,3H),6.91(d,J=16.1Hz,1H),6.31(s,1H),5.78(s,2H),4.22(t,J=5.9Hz,2H),3.55(s,3H),3.53(s,2H),1.96–1.87(m,2H);MS(ESI):m/z 484.1[M+H] + .
Example E57 (E) -5- (4-chlorobenzyl) -6- (2-cyclopentylprop-1-en-1-yl) -3- (3-hydroxypropyl) -1-methyl-1, 5-dihydro-2H-pyrrolo [3,2-d ] pyrimidine-2, 4 (3H) -dione
Pinacol diboron (1.05g, 4.134mmol), potassium tert-butoxide (536mg, 4.785mmol) and IMesCuCl (5mg, 0.012mmol) were dissolved in THF in this order, cooled to 0 ℃ under nitrogen protection and stirred for 10min. Cyclopentylacetylene (300mg, 3.191mmol) and CH were added 3 I (1.359g, 9.574mmol) and stirred at room temperature for 12h. TLC showed completion of the reaction, EA/saturated NH 4 And (3) distributing the Cl aqueous solution, separating an organic phase, drying by using anhydrous sodium sulfate, separating by using a flash silica gel chromatographic column, eluting by using PE/EA as a mobile phase, collecting a target product part, and evaporating to dryness to obtain 350mg of jelly, namely an intermediate INT 57-1.
INT 55-8(25mg,0.049mmol)、INT 57-1(34.7mg,0.147mmol)、Pd(dppf)Cl 2 (5.38mg,0.007mmol)、Cs 2 CO 3 (48mg, 0.147mmol), 1, 4-dioxane 10mL, and H 2 O3 mL was placed in a pressure tube, degassed with nitrogen for 3min, sealed, and heated at 100 ℃ for 2h. After cooling, diluting with ethyl acetate, filtering to remove insoluble substances, and evaporating the filtrate under reduced pressure to obtain a crude product. Then, the mixture was separated by flash silica gel chromatography, eluted with MeOH/DCM as a mobile phase, and the desired product fractions were collected and evaporated to dryness to obtain 25mg of a gum. The crude product was purified by preparative liquid chromatography, eluted with acetonitrile/water system as mobile phase, the target product fraction was collected and evaporated to dryness to give 18mg of a white solid, example E57. 1 H-NMR(500MHz,Chloroform-d)δ7.29–7.25(m,2H),7.13–6.99(m,2H),6.05(d,J=1.6Hz,1H),5.94(s,1H),5.59(s,2H),4.20(q,J=6.1Hz,2H),3.53(d,J=5.3Hz,2H),3.51(s,3H),2.65–2.50(m,1H),1.92(d,J=5.8Hz,2H),1.89(d,J=1.3Hz,3H),1.87–1.78(m,2H),1.77–1.68(m,2H),1.67(s,2H),1.50–1.36(m,2H);MS(ESI):m/z 456.2[M+H] + .
Example E58 (E) -7- (4-chlorobenzyl) -8- (2-cyclopentylprop-1-en-1-yl) -1- (3-hydroxypropyl) -3-methyl-3, 7-dihydro-1H-purine-2, 6-dione
INT 2-2(100mg,0.196mmol)、INT 57-1(115.6mg,0.49mmol)、Pd(dppf)Cl2(21.5mg,0.029mmol)、Cs 2 CO 3 (191mg, 0.588 mmol), 1, 4-dioxane 10mL, and H 2 O3 mL was placed in a pressure tube, degassed with nitrogen for 3min, sealed, and heated at 100 ℃ for 2h. After cooling, it was diluted with ethyl acetate and filteredRemoving insoluble substances, and evaporating the filtrate under reduced pressure to obtain crude product. Separating with flash silica gel chromatography column, eluting with MeOH/DCM as mobile phase, collecting target product, and evaporating to dryness to obtain 80mg of jelly, i.e. intermediate INT 58-2.
Intermediate INT 58-2 (80mg, 0.191mmol) was dissolved in 2mL DCM, then 0.4mL TFA was added, stirred at RT for 1h, TLC indicated complete reaction. The solvent was evaporated under reduced pressure and the residue was purified by preparative liquid chromatography using acetonitrile/water system as mobile phase, the target product fraction was collected and evaporated to dryness to obtain 50mg of white solid, example E58. 1 H-NMR(500MHz,Chloroform-d)δ7.31(d,J=8.2Hz,2H),7.17(d,J=8.3Hz,2H),6.10(s,1H),5.52(s,2H),4.20(h,J=7.1,6.6Hz,2H),3.63(s,3H),3.56(t,J=5.5Hz,2H),2.63(ddd,J=17.0,9.6,7.4Hz,1H),2.30–2.12(m,3H),1.99–1.79(m,4H),1.78–1.56(m,4H),1.54–1.40(m,2H);MS(ESI):m/z 457.2[M+H] + .
EXAMPLE E59 (E) -5- (4-chlorobenzyl) -6- (3, 3-dimethylbut-1-en-1-yl) -3- (3-hydroxypropyl) -1-methyl-1, 5-dihydro-2H-pyrrolo [3,2-d ] pyrimidine-2, 4 (3H) -dione
The synthesis of example E59 was performed as in E56, except that (E) - (4-chlorostyryl) boronic acid was replaced with pinacol trans- (3, 3-dimethylbuten-1-yl) boronic acid ester. 1 H NMR(500MHz,Chloroform-d)δ7.30(d,J=8.0Hz,2H),7.12–7.06(m,2H),6.37(d,J=16.0Hz,1H),6.19(d,J=16.0Hz,1H),6.10(s,1H),5.67(s,2H),4.26–4.12(m,2H),3.53(d,J=5.4Hz,2H),3.51(d,J=2.2Hz,3H),1.91(p,J=5.8Hz,2H),1.10(s,9H);MS(ESI):m/z 430.2[M+H] + .
Example E60- (4-chlorobenzyl) -6- (3, 3-dimethylbut-1-yn-1-yl) -3- (3-hydroxypropyl) -1-methyl-1, 5-dihydro-2H-pyrrolo [3,2-d ] pyrimidine-2, 4 (3H) -dione
INT 55-8(40mg,0.094mmol)、PdCl 2 (Ph 3 P) 2 (9.9mg, 0.014mmol), cuI (5.36mg, 0.028mmol), triethylamine 3mL, and DMF 1mL were placed in a pressure resistant tube and degassed with nitrogen for 3min, then 3, 3-dimethyl-1-butyne (38.8mg, 0.471mmol) was added and degassed for 1min. The pressure tube was sealed and heated at 60 ℃ for 4h. After cooling, the mixture was diluted with ethyl acetate, the insoluble matter was removed by filtration, and the filtrate was evaporated to dryness under reduced pressure to give a crude product. Then, the mixture was separated by flash silica gel chromatography, eluted with MeOH/DCM as a mobile phase, and the desired product fractions were collected and evaporated to dryness to give 35mg of a gum. The crude product was purified by preparative liquid chromatography, eluted with acetonitrile/water system as mobile phase, the target product fraction was collected and evaporated to dryness to give 20mg of a white solid, example E60. 1 H-NMR(500MHz,Chloroform-d)δ7.30(t,J=2.3Hz,4H),6.12(s,1H),5.61(s,2H),4.19(q,J=6.1Hz,2H),3.52(t,J=5.5Hz,2H),3.45(s,3H),1.90(p,J=5.6Hz,2H),1.35(s,9H);MS(ESI):m/z 428.2[M+H] + .
Example E61- (4-chlorobenzyl) -3- (3-hydroxypropyl) -1-methyl-6- (phenylethynyl) -1, 5-dihydro-2H-pyrrolo [3,2-d ] pyrimidine-2, 4 (3H) -dione
The synthesis of example E61 is as for E60 except that phenylacetylene is used as starting material instead of 3, 3-dimethyl-1-butyne. 1 H-NMR(500MHz,Chloroform-d)δ7.56–7.51(m,2H),7.47–7.40(m,3H),7.39–7.30(m,4H),6.29(s,1H),5.72(s,2H),4.30–4.14(m,2H),3.57–3.52(m,2H),3.50(s,3H),1.92(p,J=5.6Hz,2H);MS(ESI):m/z 448.1[M+H] + .
2. Pharmacological examples
Determination of TRPC4 and TRPC5 inhibitory Activity
HEK-293 cells expressing hTRPC4 or hTRPC5 were inoculated into PDL-coated black-walled-bottom-permeable 96-well plates, 2X 10 cells per well 4 Culturing the cells for 8 hr, discarding the original culture medium, adding 60 μ L of Fluo-4/AM dye with final concentration of 4 μ M, incubating at 37 deg.C for 60 min, rinsing with calcium flow detection buffer 5 times, and mixingThe cell plate is placed in a preheating chamber at 30 DEG C(Molecular Devices, sunnyvale, calif., USA), excited at a wavelength of 488nm and fluorescent signals were recorded continuously at a sampling frequency of 1s over the range of 515-535 nm. After 60 seconds of recording, the signal acquisition is continued for 300s by adding the solvent control, test compound and positive inhibitor HC608 (final concentration of 100 nM), followed by the addition of the agonist Englerin A (EA) (final concentration of 0.3 nM) and continued for 600 seconds fluorescence signal. Trace plot fluorescence signal F/F 0 Wherein F is the fluorescence signal at different time points, F 0 The base fluorescence signal, i.e. the average of the fluorescence signals at the first 10 time points, is used. Dose-effect diagram is firstly expressed as F/F 0 With =1 as baseline, the area under the curve of the change in fluorescence intensity after addition of EA was calculated, and log [ Inhibitor ] was used in combination with the area under the curve and the log of the compound concentration]response-Variable slope computing IC 50 The value is obtained.
2. Determination of stability of liver microsomes
First, 0.1M Tris buffer, pH 7.4, was prepared, and then MgCl was prepared at a concentration of 100mM using this buffer 2 A solution and a coenzyme factor NADPH solution with a concentration of 10 mM. Test compounds were first formulated from DMSO into stock solutions, which were then diluted with water and 0.1% bsa to working concentrations as applicable. For the measurement, TRIS buffer (final concentration of microsomal protein 0.33 mg/mL) of liver microsomes and MgCl were added 2 The solution (final concentration: 5 mM), the test compound solution (final concentration: 1. Mu.M) and the NADPH solution (final concentration: 1 mM) were incubated at 37 ℃ and the reaction was stopped by adding methanol for 0, 7, 17, 30 and 60 minutes, respectively. The remaining concentration of the test compound was determined by LC/MS/MS method. Calculation of half-life: t is a unit of 1/2 =0.693/k e 。k e Is the slope (absolute value) of the linear regression line when plotted semilogarithmically. The remaining percentage of substrate was taken as a semilog and a semilog plot was made of reaction time.
3. Evaluation results of Activity and microsomal stability
TRPC4/5 inhibitory activity and liver microsome stability are shown in the following table:
note: -, not tested.
Compound C31 in the above table is compound 31 at pages 169, 256 and C297 is compound 297 at pages 210, 301 in patent application WO2014143799, which are both potent TRPC5 inhibitors. C31 is also known in the literature as HC-608 and Pico145 (PLoS ONE.2018,13, e0191225.). As can be seen from the assay results, many compounds represented by the general formula (I) of the present invention, including compound E37 structurally close to C297, unexpectedly exhibited stronger TRPC4 and TRPC5 inhibitory activities and faster liver microparticle metabolic rates than C31 and C297. Patent application WO2014143799 discloses the use of compound C31 in the treatment of neuropsychiatric diseases such as depression, anxiety and the like, and patent application US20220031706 discloses the use of compound C31 in the treatment of metabolic diseases such as diabetes, obesity and the like. The invention discloses application of a compound represented by a general formula (I) and represented by a compound E37 to treatment of skin diseases such as psoriasis. When used as a skin topical drug, the compound is absorbed transdermally to exert its pharmacological effect and then taken into the blood circulation. If the compound is cleared more rapidly by liver metabolism, it is predicted that systemic side effects can be avoided more effectively with better safety.
4. Evaluation of hepatorenal cytotoxicity of Compounds
4.1 isolation of mouse Primary hepatocytes and evaluation of toxicity
Male C57/BL-6 mice 2 months old were anesthetized with tribromoethanol, and were fixed on the bench with the abdomen facing up. First 100mL of Ca-free solution 2+ HBSS buffer (containing 5.5mM glucose and 2mM HEPES, pH = 7.4) was fed at a rate of 4-5mL/minPerfusing the liver with a solution containing 5mM Ca 2+ And 0.05% collagenase IV were perfused in the liver for 10min. The resulting cell suspension was filtered through two nylon meshes with a mesh size of 70 μm, and then centrifuged at 50 Xg for 2 minutes at 4 ℃ to collect cell masses. The cell pellet was resuspended in 50mL of solution, 12.5mL of which was taken and 10.8mL of Percoll solution and 1.2mL of 10-fold concentrated DMEM solution (containing 4.5g/l glucose) were added. The mixture was centrifuged at 500g for 5 minutes and the cell pellet was washed twice with DMEM solution. By morphological analysis, 95% of the isolated cells were judged as hepatocytes. Cell viability was between 85% and 95% as determined by trypan blue exclusion.
Isolated mouse primary hepatocytes were seeded in 96-well culture plates (1.5X 10) 4 Individual cells/well) were cultured in low sugar DMEM containing 10% fetal bovine serum and 100 units/ml penicillin and streptomycin. After 4 hours of culture, serum-free DMEM was replaced. Test compounds were pre-dissolved in DMSO to make 100mM stock solutions, which were then diluted to the indicated concentrations with serum-free DMEM. mu.L of the compound was added to the wells to give a final concentration of 1 or 10. Mu.M, and the incubation was continued for 24 hours. The medium was then removed and the cells were incubated with 0.5mg/mL MTT (in medium) for an additional 2 hours at 37 ℃. After removing the supernatant, 150. Mu.L of dimethyl sulfoxide was added to each well, and the absorbance at 570nm was measured.
4.2 HK-2 Kidney cell culture and toxicity evaluation
After recovery of commercially available HK-2 kidney cells, 96-well plate cultures were performed using DMEM/F12 complete medium containing penicillin/streptomycin, HEPES (4-hydroxyethylpiperazineethanesulfonic acid), and 10% fetal bovine serum, seeded at approximately 2.5X 10 per well 3 And (4) cells. After culturing for about 24 hours, the culture medium was removed, 100. Mu.L of a medium diluent of the test compound prepared in advance was added to the medium diluent so that the final concentration of the test compound was 1 or 10. Mu.M, and the culture was continued for 24 hours. The medium was then removed and the cells were incubated with 0.5mg/mL MTT (in medium) for an additional 2 hours at 37 ℃. After removing the supernatant, 150. Mu.L of dimethyl sulfoxide was added to each well, and the absorbance at 570nm was measured.
4.3 toxicity assay results
The results of the hepatorenal cytotoxicity assays for the compounds are shown in the following table:
note: -, cell viability is not reduced; +, cell viability decreased by 10-30%; + + +, cell viability decreased 30-60%; (ii) a + + + +, cell viability decreased 60-90%.
From the measurement results, compared with the compounds C31 and C297 disclosed in patent application WO2014143799, the compound represented by the general formula (I) in the invention has smaller influence on the viability of liver and kidney cells and shows lower cytotoxicity.
5. Effect of Compounds on keratinocyte proliferation
5.1 culture of the human immortalized keratinocyte cell line HaCaT
HaCaT cells cultured in DMEM medium containing 10% FBS, 10mM HEPES and 100U/mL penicillin/streptomycin at 37 ℃ 5% CO 2 And cultured in 95% humidity. When the cells grow to 70-80% confluence, discarding the old culture medium, rinsing with PBS for 2 times, adding pancreatin-EDTA, digesting at 37 ℃ for 5-7 minutes, when the cells become round and the cell gaps become larger, adding DMEM containing FBS to stop digestion, blowing the cells with a pipette, collecting the cell suspension, centrifuging at 800rpm for 5 minutes, discarding the supernatant, resuspending the cells with 10% FBS of DMEM, taking a part of the cell suspension, transferring into a new cell bottle, and continuing culturing. Or after adjusting the cell concentration with DMEM containing 2% FBS, the cells were plated on a cell plate and used for the next experiment.
5.2 BrdU incorporation experiments
Adding 10 μ MBrdU (5-bromodeoxyuridine) into cell culture environment, culturing at 37 deg.C for 3 hr, removing the solution in the wells, and rinsing with PBS for 3 times; fixing the cells with 4% paraformaldehyde for 30 minutes, and rinsing with PBS for 3 times; 0.1% TritonX-100 cells were treated for 15 minutes and rinsed 3 times with PBS; then, the mixture was treated with 2M HCl for 30 minutes, neutralized with 0.1M boric acid for 10 minutes, rinsed with PBS for 3 times, and then blocked with 5% BSA dropwise at room temperature for 30 minutes; after discarding the liquid, 1. The next day, primary antibody is discarded, and PBS is used for rinsing for 5 times; dripping 1; under the condition of keeping out of the light, 1. Under an inverted fluorescence microscope, 5-6 fields were randomly selected for observation and photographing.
5.3 results of the experiment
As shown in fig. 1, the proliferating HaCaT cells contained BrdU, so the positive nuclei exhibited red fluorescence (as indicated by white triangles); while Hoechst dye stains all nuclei blue. The number of positive cells in HaCaT cells in the Veh group accounts for 1.7 +/-1.2% of the total number of cells, and the ratio of the proliferated HaCaT cells is increased to 5.8 +/-1.0% after being stimulated by 100ng/mL IL-17 for 12 hours; haCaT cells were treated alone at 100nM E37 for 12 hours, with a cell proliferation rate of 2.0 + -1.4%, with insignificant differences (P > 0.05) relative to the Veh group; haCaT cells treated by 100nM E37 and 100ng/mL IL-17 for 12 hours have a cell proliferation rate of 2.7 + -0.6%, which is significantly lower than that of IL-17 treated group (P < 0.01).
6. Evaluation of efficacy of compound in treating psoriasis
6.1 pharmaceutical cream formulation Process
The pharmaceutical cream formulations are shown in the following table:
preparation of an aqueous phase: weighing ethanol according to the prescription amount, adding E37, stirring for dissolving, sequentially adding Tween 80, sodium dodecyl sulfate, glycerol, isopropyl myristate, methyl hydroxybenzoate, azone and purified water into a beaker, and stirring until the mixture is uniformly dispersed.
Preparing an oil phase: weighing the glyceryl monostearate, the palmitic acid and the white vaseline with the prescription amount in a beaker, and heating and dissolving the mixture in a water bath at the temperature of 80 ℃ until the mixture is liquid.
Slowly adding the water phase into the oil phase under stirring, taking out from the water bath, and stirring at room temperature until cooling to obtain cream.
6.2 Imiquemode-induced psoriasis model in mice
24C 57BL/6 mice, each half male and female, purchased from the laboratory animal center of Nanjing university of medical science, weighing 22-23g. The mice were shaved of their back hair and were divided into 4 groups by sex: control group (Vas), modeling group (IMQ), modeling group + mometasone furoate group (IMQ + Mome), and modeling group + E37 cream group (IMQ + E37), each group containing 6 animals. Before the experiment, the mice are placed in a quiet environment and a light-proof environment for feeding for 3 days to adapt to the environment, the time ratio of illumination to darkness is 1, the room temperature is controlled to be 25 ℃, the humidity is 55%, and the mice can freely eat and drink water.
62.5mg of 5% (0.1g. After 6 hours of application of IMQ or Vas each day, 100mg of positive drug Mometasone furoate cream (Mometasone, mome, shanghai zhengda general pharmaceutical products gmbh) or E37 cream was applied, and the Vas group was administered with the same dose of Vas. The skin of the back of the mice was recorded by photographing on the day 1,3,5 of molding, and the appearance of the skin on the day 5 of molding is shown in fig. 2.
6.3 evaluation of clinical symptoms
The clinical symptoms of the Psoriasis model of the mice are evaluated from 3 indexes of erythema, scale and infiltration thickening by adopting a Psoriasis Area and Severity Index (PASI) scoring standard, scoring is carried out according to 0-4 minutes, and the integrals of the 3 indexes are added to obtain a total integral. PASI scoring criteria are as follows: 0 point, no symptom; 1 minute, light; 2 points, medium; 3 points, severe; 4 points, extremely severe. Single-blind evaluations and photographic recordings were performed daily by trained experimenters prior to application of the IMQ cream. The scoring results are shown in the following table: the measured data are expressed as mean ± standard deviation (mean ± SEM), and measured by two-way anova, in which analysis results, ap<0.01, relative to the Vas group; # P<0.05, ## P<0.01, relative to the IMQ group.
6.4 histopathological examination
Skin tissues of the drug administration area on the back of the mouse were collected, fixed in 4% (mass fraction) paraformaldehyde solution for 48 hours, embedded in paraffin and sectioned at 3 μm for Hematoxylin-Eosin (H)&E) And (6) dyeing. The thickness of the epidermis layer of the skin was measured using NIS-element BR software by observing and photographing using an Eclipse Ti type inverted microscope at a magnification of 100, and 3 fields of view were randomly selected for each section. Note: the measured data are expressed as mean + -standard deviation (mean + -SEM) and measured using one-way anova, where P is the measured result<0.01, relative to the Vas group; ## P<0.01, relative to the IMQ group.
6.5 results of the experiment
6.5.1E37 cream Effect on Back skin appearance and PASI score in psoriasis mice
Throughout the experiment, the back skin of Vas mice was consistently smooth and flat without erythema, scaling, thickening, etc. (fig. 2). The back skin of IMQ group mice has obvious psoriasis-like symptoms such as erythema, scale, thickening and the like on the 3 rd day of model building, the symptoms are obviously increased along with the model building (figure 2), and the erythema, scale (shown as black triangles) and thickening are the most serious on the 5 th day; their PASI scores showed a gradual increase in PASI scores in IMQ group mice, and the IMQ group was significantly different from the Vas group starting on day 3 (P < 0.01) (table 1). The smearing of the positive medicament Mome can improve the appearance of psoriasis-like symptoms such as erythema, scale, thickening and the like caused by IMQ (figure 2); PASI scores showed a slow increase in PASI scores for IMQ + Mome group mice, with statistically significant (P < 0.01) scores for IMQ + Mome group PASI significantly lower than IMQ group starting on day 4 (table 1). The application of the E37 cream can slightly improve erythema, scales and thickened psoriasis-like symptoms of the back skin of the mice (figure 2), and the erythema, scales (shown by black triangles) and thickened symptoms of the IMQ + E37 group are reduced to some extent compared with the IMQ group at the 5 th day (figure 2), but the improvement effect is weaker than that of the positive medicine Mome; PASI scores showed a slow increase in PASI scores for IMQ + E37 group mice, with PASI scores for IMQ + E37 group being lower than IMQ group by day 4, statistically significant (P < 0.05) (table 1).
TABLE 1 dorsal skin PASI score in groups of mice
6.5.2 Effect of E37 cream on Back skin pathology in psoriasis mice
As shown in fig. 3, the tissue structure of the back skin of Vas mice was not significantly abnormal, the horny layer was completely keratinized, the boundary between the epidermis layer and the dermis layer was clear, and the infiltration of inflammatory cells was less; the thickness of the epidermis layer was measured to be 25.72. + -. 1.19. Mu.m. IMQ group mice had excessive thickening of the epidermal layer of the dorsal skin tissue (as indicated by white lines), keratosis of the stratum corneum with visible accumulation of inflammatory cells in the stratum corneum (as indicated by black arrows), edema of the dermis with massive inflammatory infiltration (as indicated by black triangles); the thickness of the epidermal layer is 108.48 +/-3.51 mu m, and is obviously increased compared with the Vas group (P < 0.01). The thickness of the epidermal layer of the dorsal skin tissue of mice in the IMQ + Mome group is 57.71 +/-2.66 mu m, the thickness is obviously reduced compared with that of the IMQ group (P is less than 0.01), no edema is seen in the dermal layer, and the infiltration degree of inflammatory cells is reduced compared with that of the IMQ group. The stratum corneum structure of the dorsal skin tissue of mice in the IMQ + E37 group was slightly restored, the thickness of the epidermal layer was 85.38 +/-3.61 μm, which was reduced compared with the IMQ group, and was statistically significant (P < 0.01), and the edema of the dermal layer was reduced compared with the IMQ group, but inflammatory cell infiltration was still observed (as shown by black triangles).
Finally, it should be noted that: the above examples are only intended to illustrate the technical solution of the present invention and not to limit it; although the present invention has been described in detail with reference to the preferred embodiments, it will be understood by those skilled in the art that various changes may be made and equivalents may be substituted for elements thereof; without departing from the spirit of the present invention, it is intended to cover all aspects of the invention as defined by the appended claims.
Claims (10)
1. Condensed pyrimidinedione compounds and pharmaceutically acceptable salts thereof are characterized in that the structural formula of the compounds is shown as formula (I),
wherein,
R 1 is C 1 -C 6 Alkyl groups of (a);
each R is 2 Independently a halogen atom;
R 3 selected from substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 3 -C 10 A substituted or unsubstituted 6-to 10-membered aryl group and a substituted or unsubstituted 5-to 8-membered heteroaryl group, wherein R 3 The substituent(s) is 1 to 3 groups selected from the group consisting of: c 1 -C 6 Alkyl of (C) 3 -C 8 Cycloalkyl of (ii), -OR 4 、-N(R 4 ) 2 And a halogen atom;
each R 4 Each independently selected from H, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 3 -C 8 A cycloalkyl group, a substituted or unsubstituted phenyl group of (a), wherein R 4 The substituents of (a) are 1 to 3 groups of the following group: c 3 -C 8 Cycloalkyl, halogen atom, hydroxyl and = O; or,
two R 4 Taken together to form a 4-to 8-membered substituted or unsubstituted heterocyclic ring, the heteroatoms of which are selected from N, O, and S and contain at least 1N, the number of heteroatoms being 1 or 2; the substituents of the heterocycle are 1-3 groups independently selected from the group consisting of: c 1 -C 6 Alkyl groups and halogen atoms of (a);
n is an integer of 1 to 3;
x is N or CH;
y is selected from one of ethynyl and substituted or unsubstituted ethenyl, the stituent of the ethenyl is 1-2C 1 -C 6 An alkyl group.
2. The compound and pharmaceutically acceptable salts thereof according to claim 1, wherein R is 1 Is methyl, ethyl or isopropyl.
3. The compound and pharmaceutically acceptable salts thereof according to claim 1, wherein R is 3 Is C 3 -C 10 Cycloalkyl OR-OR of 4 、-N(R 4 ) 2 Substituted C 1 -C 6 Alkyl group of (1).
4. The compound of claim 1, and pharmaceutically acceptable salts thereof, wherein the compound is selected from the group consisting of structural formulas (IIa) - (IIc):
wherein,
R 1 is methyl, ethyl or isopropyl;
each R 2 Each independently is a halogen atom;
ring C is substituted or unsubstituted C 3 -C 10 Substituted or unsubstituted phenyl or substituted or unsubstituted 5-to 8-membered heteroaryl, wherein the substituents of ring C are 1 to 3 groups selected from: c 1 -C 6 Alkyl groups and halogen atoms of (b);
R 4 each independently selected from substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 3 -C 8 A cycloalkyl group, a substituted or unsubstituted phenyl group of (a), wherein R 4 The substituent(s) is 1 to 3 groups selected from the group consisting of: c 3 -C 8 Cycloalkyl group and halogen atom of (b); or,
two R 4 Together with N to form a 4-to 8-membered substituted or unsubstituted heterocycle having 1 to 3C substituents 1 -C 6 Alkyl groups of (a);
R 5 、R 6 each independently is H or C 1 -C 3 Alkyl groups of (a);
n is an integer of 1 to 3.
6. use of a compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, for use as a TRPC4 and TRPC5 inhibitor or for the manufacture of a medicament for the treatment of a disease associated with abnormal TRPC4 or/and TRPC5 function, expression.
7. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
8. The pharmaceutical composition according to claim 7, wherein the pharmaceutical composition is for the treatment of a skin disorder associated with keratinocyte cell abnormalities.
9. The pharmaceutical composition of claim 8, wherein the disease is psoriasis, ichthyosis, keratopalmoplantar, olmsted, cutis Bufonis, or menopausal keratoderma.
10. The pharmaceutical composition of claim 8, wherein the pharmaceutical composition is for topical application to the skin.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211324140.5A CN115636831A (en) | 2022-10-27 | 2022-10-27 | Fused pyrimidinediones, their use and pharmaceutical compositions |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211324140.5A CN115636831A (en) | 2022-10-27 | 2022-10-27 | Fused pyrimidinediones, their use and pharmaceutical compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115636831A true CN115636831A (en) | 2023-01-24 |
Family
ID=84947536
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211324140.5A Pending CN115636831A (en) | 2022-10-27 | 2022-10-27 | Fused pyrimidinediones, their use and pharmaceutical compositions |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115636831A (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101631788A (en) * | 2006-12-22 | 2010-01-20 | 施瓦茨制药有限公司 | 8-alkynyl xanthine and derivative |
WO2014152287A2 (en) * | 2013-03-14 | 2014-09-25 | Hydra Biosciences, Inc. | Substituted xanthines and methods of use thereof |
CN105143229A (en) * | 2013-03-15 | 2015-12-09 | 海德拉生物科学有限公司 | Substituted xanthines and methods of use thereof |
CN112771032A (en) * | 2018-10-29 | 2021-05-07 | 江苏先声药业有限公司 | Pyrimidine pyrazole compounds as fourth generation EGFR inhibitors |
-
2022
- 2022-10-27 CN CN202211324140.5A patent/CN115636831A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101631788A (en) * | 2006-12-22 | 2010-01-20 | 施瓦茨制药有限公司 | 8-alkynyl xanthine and derivative |
WO2014152287A2 (en) * | 2013-03-14 | 2014-09-25 | Hydra Biosciences, Inc. | Substituted xanthines and methods of use thereof |
CN105143229A (en) * | 2013-03-15 | 2015-12-09 | 海德拉生物科学有限公司 | Substituted xanthines and methods of use thereof |
CN112771032A (en) * | 2018-10-29 | 2021-05-07 | 江苏先声药业有限公司 | Pyrimidine pyrazole compounds as fourth generation EGFR inhibitors |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103717599B (en) | Indazole | |
CN103153994B (en) | Bicyclic heteroaryl kinase inhibitor and using method | |
JP5154728B2 (en) | Substituted 5-alkynylpyrimidines with neurotrophic activity | |
CN107001378B (en) | Pyrrolopyrimidine compounds | |
CN102232076B (en) | Pyrrolopyrazinyl urea kinase inhibitors | |
JP6948659B1 (en) | Pyridadinyl thiaazole carboxamide compound | |
EP2726482B1 (en) | Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors | |
EP3541373B1 (en) | Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels | |
CN102827170A (en) | Active treatment compositions and use method thereof | |
CN102827073A (en) | Therapeutically active compositions and application methods thereof | |
BRPI0708331A2 (en) | pyrimidinyl sulfonamide compounds that inhibit vla-4 mediated leukocyte adhesion | |
EP1661896A1 (en) | Pyrrolopyrimidinethione derivative | |
TW200811181A (en) | Purinone derivatives as HM74a agonists | |
TW200900395A (en) | Heteroarylamide pyrimidone compounds | |
EP4375274A1 (en) | Annulated pyridazine compound | |
TW201623307A (en) | Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors | |
CN109311891A (en) | The crystallization of Pyrrolopyrimidine compounds as JAK inhibitor | |
DK2776387T3 (en) | Tricyclic amino containing compounds to treat or prevent symptoms associated with endocrine dysfunction | |
CN102762554A (en) | (r)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2h-pyran-4-ol, a partial agonist of 5-ht4 receptors | |
CA2995325A1 (en) | Isothiazole derivative | |
KR20080032104A (en) | Halogenated pyrazolo [1,5-a]pyrimidines, processes, uses as gaba-a receptors ligand, compositions and intermediates | |
CN116568301A (en) | Bicyclic compounds for treating diseases and uses thereof | |
CN109867675B (en) | Pyrrolopyrimidine derivative compound, pharmaceutical composition and application thereof | |
JP2005519087A (en) | 1- [alkyl], 1-[(heteroaryl) alkyl] and 1-[(aryl) alkyl] -7- (pyrimidin-4-yl) -imidazo [1,2-a] pyrimidine-5 (1H)- ON derivative | |
WO2020020377A1 (en) | Fused ring derivative used as fgfr4 inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20230511 Address after: No. 639 Jiangning longmian Road District of Nanjing City, Jiangsu province 211198 Applicant after: CHINA PHARMACEUTICAL University Applicant after: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES Address before: No. 639 Jiangning longmian Road District of Nanjing City, Jiangsu province 211198 Applicant before: CHINA PHARMACEUTICAL University |
|
TA01 | Transfer of patent application right |